PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 12606689-4 2003 The current through delta2(A654T) channels was reduced by pentamidine and 9-tetrahydroaminoacridine, antagonists that also inhibit NR1/NR2B NMDA receptors but not AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. Pentamidine 58-69 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 131-134 12606689-4 2003 The current through delta2(A654T) channels was reduced by pentamidine and 9-tetrahydroaminoacridine, antagonists that also inhibit NR1/NR2B NMDA receptors but not AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. Pentamidine 58-69 glutamate receptor ionotropic, NMDA 2B Xenopus laevis 135-139 12606689-6 2003 Pentamidine inhibited a constitutively active NR1(T648A)/NR2B NMDA receptor in a manner similar to its inhibition of a glutamate-gated wild-type NMDA receptor, but different from its inhibition of constitutively active delta2(A654T) receptors. Pentamidine 0-11 glutamate ionotropic receptor NMDA type subunit 1 L homeolog Xenopus laevis 46-49 12606689-6 2003 Pentamidine inhibited a constitutively active NR1(T648A)/NR2B NMDA receptor in a manner similar to its inhibition of a glutamate-gated wild-type NMDA receptor, but different from its inhibition of constitutively active delta2(A654T) receptors. Pentamidine 0-11 glutamate receptor ionotropic, NMDA 2B Xenopus laevis 57-61 10404264-3 1999 Sinefungin exerted an inhibitory effect when added within 4 h after sporozoite addition to HCT-8 cultures (MIC50 = 38 mumol L-1), while the inhibitory effects of paromomycin and pentamidine dimethanesulfonate were also easily detected (MIC50 = 0.87 mumol L-1 and 0.27 mumol L-1, respectively). Pentamidine 178-208 immunoglobulin kappa variable 1-16 Homo sapiens 255-258 12743807-4 2003 So far the treatment for the early stage of HAT involves the drugs pentamidine and suramin which have been very successful. Pentamidine 67-78 transmembrane serine protease 11D Homo sapiens 44-47 12803856-5 2003 When the THP1 cells were treated with SAG or pentamidine, their expression of the receptor was increased. Pentamidine 45-56 GLI family zinc finger 2 Homo sapiens 9-13 12516958-5 2002 Pentamidine at a tolerable dose markedly inhibited the growth of WM9 human melanoma tumors in nude mice coincident with the induction of tumor cell necrosis and is capable of inactivating ectopically expressed PRL-2 in the cancer cells. Pentamidine 0-11 protein tyrosine phosphatase 4a2 Mus musculus 210-215 11734561-9 2002 In addition, ADOMETDC overproduction in wild type parasites alleviated the toxic effects of 5"-(((Z)-4-amino-2-butenyl)methylamino)-5"-deoxyadenosine (MDL 73811), but not pentamidine, berenil, or methylglyoxyl bis(guanylhydrazone), all inhibitors of ADOMETDC activities in vitro. Pentamidine 171-182 S-adenosylmethionine decarboxylase Leishmania donovani 13-21 10490599-9 1999 Since PNT1 was previously described as a gene affecting resistance to the antibiotic pentamidine, our data support a mitochondrial target for this drug. Pentamidine 85-96 Pnt1p Saccharomyces cerevisiae S288C 6-10 10404264-3 1999 Sinefungin exerted an inhibitory effect when added within 4 h after sporozoite addition to HCT-8 cultures (MIC50 = 38 mumol L-1), while the inhibitory effects of paromomycin and pentamidine dimethanesulfonate were also easily detected (MIC50 = 0.87 mumol L-1 and 0.27 mumol L-1, respectively). Pentamidine 178-208 immunoglobulin kappa variable 1-16 Homo sapiens 255-258 9201604-0 1997 A pentamidine-treated acquired immunodeficiency syndrome patient associated with sudden onset diabetes mellitus and high tumor necrosis factor alpha level. Pentamidine 2-13 tumor necrosis factor Homo sapiens 121-148 9527814-0 1998 QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Pentamidine 93-103 QacA Staphylococcus aureus 0-4 8937715-8 1996 The cholinesterase inhibitor, tacrine (1 microM), potentiated the effect of pentamidine; in contrast, morphine inhibited pentamidine-induced responses. Pentamidine 76-87 butyrylcholinesterase Homo sapiens 4-18 9182817-10 1997 TBT-induced accumulation of skin water and TNF production were significantly reduced by topical treatment with dexamethasone and pentamidine, two anti-inflammatory agents. Pentamidine 129-140 tumor necrosis factor Mus musculus 43-46 9255333-6 1997 Aerosolized pentamidine is probably the best alternative considering its similar results in primary prophylaxis for patients with a CD4 count > or = 100/mm3. Pentamidine 12-23 CD4 molecule Homo sapiens 132-135 8841838-2 1996 We now report that pentamidine inhibited the human whole blood production of the chemotactic cytokines (chemokines) interleukin (IL)-8, growth related gene alpha (GRO alpha) and monocyte chemotactic protein-1 (MCP-1). Pentamidine 19-30 C-X-C motif chemokine ligand 8 Homo sapiens 116-134 8905336-6 1996 A similar effect was achieved with pentamidine (10%), another type of calmodulin antagonist, but not with ketoconazole, a weak calmodulin antagonist. Pentamidine 35-46 calmodulin 2 Mus musculus 70-80 8841838-2 1996 We now report that pentamidine inhibited the human whole blood production of the chemotactic cytokines (chemokines) interleukin (IL)-8, growth related gene alpha (GRO alpha) and monocyte chemotactic protein-1 (MCP-1). Pentamidine 19-30 C-X-C motif chemokine ligand 1 Homo sapiens 163-172 8841838-2 1996 We now report that pentamidine inhibited the human whole blood production of the chemotactic cytokines (chemokines) interleukin (IL)-8, growth related gene alpha (GRO alpha) and monocyte chemotactic protein-1 (MCP-1). Pentamidine 19-30 C-C motif chemokine ligand 2 Homo sapiens 178-208 8841838-2 1996 We now report that pentamidine inhibited the human whole blood production of the chemotactic cytokines (chemokines) interleukin (IL)-8, growth related gene alpha (GRO alpha) and monocyte chemotactic protein-1 (MCP-1). Pentamidine 19-30 C-C motif chemokine ligand 2 Homo sapiens 210-215 8841838-5 1996 Time course experiments indicated that pentamidine (10 microM) retained its ability to inhibit PHA-stimulated IL-8 production even when its addition was delayed for up to 24h after mitogen stimulation. Pentamidine 39-50 C-X-C motif chemokine ligand 8 Homo sapiens 110-114 8701416-0 1996 Pentamidine is a specific, non-peptide, GPIIb/IIIa antagonist. Pentamidine 0-11 integrin subunit alpha 2b Homo sapiens 40-45 8735833-0 1996 New pentamidine related substances which simultaneously inhibit platelet aggregation and accelerate plasmin generation and in vitro clot lysis. Pentamidine 4-15 plasminogen Homo sapiens 100-107 8735833-5 1996 Two (assigned as D-2 and D-3) of the synthetic pentamidine-guanidino related molecules were able to inhibit platelet aggregation and simultaneously accelerate in vitro plasmin generation and clot-lysis in the nM range. Pentamidine 47-58 plasminogen Homo sapiens 168-175 8701416-7 1996 Pentamidine partially, but significantly, inhibited lysosome and alpha-granule release induced by the thrombin agonist peptide, while RGDS had no effect. Pentamidine 0-11 coagulation factor II, thrombin Homo sapiens 102-110 8701416-10 1996 Thus, pentamidine is a non-peptide GPIIb/IIIa antagonist that is non-activating and is specific for GPIIb/IIIa. Pentamidine 6-17 integrin subunit alpha 2b Homo sapiens 35-40 8701416-10 1996 Thus, pentamidine is a non-peptide GPIIb/IIIa antagonist that is non-activating and is specific for GPIIb/IIIa. Pentamidine 6-17 integrin subunit alpha 2b Homo sapiens 100-105 8564607-8 1995 However, the bioassays showed that the following drugs reduced the activity of aldesleukin: ganciclovir sodium, lorazepam, pentamidine isethionate, prochlorperazine edisylate, and promethazine hydrochloride. Pentamidine 123-146 interleukin 2 Homo sapiens 79-90 8564607-10 1995 Aldesleukin 33,800 IU/mL in 5% dextrose injection lost significant biological activity in the presence of prochlorperazine edisylate, promethazine hydrochloride, lorazepam, ganciclovir sodium, and pentamidine isethionate during simulated Y-site administration. Pentamidine 197-220 interleukin 2 Homo sapiens 0-11 7542607-4 1995 The inhibition by pentamidine was prevented by the addition of purified calmodulin. Pentamidine 18-29 calmodulin 1 Rattus norvegicus 72-82 8545317-9 1995 Increasing use of somatostatin, particularly in HIV patients often given other hyperglycaemia inducing drugs such as didanosine, pentamidine, dapsone, and phenytoin should be accompanied with careful monitoring of blood glucose levels. Pentamidine 129-140 somatostatin Homo sapiens 18-30 7712230-5 1995 In a model with four covariates (CD4+ cells, phase angle, pentamidine, azidothymidine), the prognostic impact of the CD4+ cell count (parameter estimate: -0.549) was lower compared with the phase angle alpha (parameter estimate: -0.799; p < or = 0.0001) and did not gain statistical significance (p = 0.0626). Pentamidine 58-69 CD4 molecule Homo sapiens 117-120 7542607-0 1995 Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist. Pentamidine 65-76 calmodulin 1 Rattus norvegicus 80-90 7542607-5 1995 In addition, pentamidine inhibited calmodulin-dependent activation of neuronal NO synthase purified from rat cerebellum. Pentamidine 13-24 calmodulin 1 Rattus norvegicus 35-45 7542607-6 1995 From these results, it is suggested that pentamidine inhibits the neuronal NO synthase activation by probably acting as a calmodulin antagonist. Pentamidine 41-52 calmodulin 1 Rattus norvegicus 122-132 7854375-6 1995 In those entering with fewer than 100 CD4+ cells per cubic millimeter, the risk was 33 percent with aerosolized pentamidine, as compared with 19 percent with trimethoprim-sulfamethoxazole and 22 percent with dapsone (P = 0.04). Pentamidine 112-123 CD4 molecule Homo sapiens 38-41 7705432-3 1994 Doses that reduced TNF levels by 50% were 0.012 mg/kg for dexamethasone, 0.06 mg/kg for R-PIA, 0.24 mg/kg for pentamidine, 6.5 mg/kg for fusidic acid and 15 mg/kg for pentoxifylline. Pentamidine 110-121 tumor necrosis factor Rattus norvegicus 19-22 7475946-1 1995 Pentamidine effects on the interferon-gamma- or interferon-gamma plus bacterial lipopolysaccharide-induction of nitric oxide synthase in the macrophage cell line RAW 264.7, determined by measuring nitrite release into culture supernatants, were investigated. Pentamidine 0-11 interferon gamma Mus musculus 27-43 7475946-1 1995 Pentamidine effects on the interferon-gamma- or interferon-gamma plus bacterial lipopolysaccharide-induction of nitric oxide synthase in the macrophage cell line RAW 264.7, determined by measuring nitrite release into culture supernatants, were investigated. Pentamidine 0-11 interferon gamma Mus musculus 48-64 7695273-0 1994 Characterization of the PNT1 pentamidine resistance gene of Saccharomyces cerevisiae. Pentamidine 29-40 Pnt1p Saccharomyces cerevisiae S288C 24-28 7711409-0 1994 Insulin-dependent diabetes mellitus following pentamidine therapy in a patient with AIDS. Pentamidine 46-57 insulin Homo sapiens 0-7 8083818-1 1994 Therapeutic concentrations (0.3-1.5 mgL-1) of pentamidine isethionate, normally obtainable in-vivo after parenteral administration of the drug, did not affect the in-vitro activity of the enzymes lysozyme, beta-glucuronidase or myeloperoxidase released from zymosan-activated human neutrophilic granulocytes. Pentamidine 46-69 LLGL scribble cell polarity complex component 1 Homo sapiens 36-41 8188907-2 1994 Our purpose is to describe three AIDS patients with low cluster differentiation cell (CD4) counts, who were receiving aerosol pentamidine prophylaxis, and who had large noncalcified hilar and mediastinal lymphadenopathy. Pentamidine 126-137 CD4 molecule Homo sapiens 86-89 8070328-0 1994 N-hydroxylation of the antiprotozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Pentamidine 42-53 LOW QUALITY PROTEIN: cytochrome P450 2C3 Oryctolagus cuniculus 80-100 8370344-9 1993 At the later time points, Pe also inhibited beta-actin, ornithine decarboxylase, and GAPDH mRNA expression, indicating that pentamidine had a general toxic effect on mRNA transcription in the macrophages. Pentamidine 26-28 POTE ankyrin domain family member F Homo sapiens 44-54 8196573-2 1994 BACKGROUND: We report on a retrospective study in 544 HIV-positive patients, (42 women, 502 men, mean age 35 years) showing CD4 lymphocyte counts below 200 c/mcl or after their cure of Pneumocystis carinii pneumonia, who received 300 mg pentamidine aerosol as prophylaxis against Pneumocystis carinii pneumonia every four week. Pentamidine 237-248 CD4 molecule Homo sapiens 124-127 8150874-3 1993 In the present assay, pentamidine was extracted from plasma using solid-phase extraction and was analyzed using a C18 column and a mobile phase containing 18% acetonitrile, 2% methanol, 0.2 M ammonium acetate and 0.5% triethylamine. Pentamidine 22-33 Bardet-Biedl syndrome 9 Homo sapiens 114-117 8370344-9 1993 At the later time points, Pe also inhibited beta-actin, ornithine decarboxylase, and GAPDH mRNA expression, indicating that pentamidine had a general toxic effect on mRNA transcription in the macrophages. Pentamidine 26-28 ornithine decarboxylase 1 Homo sapiens 56-79 8370344-9 1993 At the later time points, Pe also inhibited beta-actin, ornithine decarboxylase, and GAPDH mRNA expression, indicating that pentamidine had a general toxic effect on mRNA transcription in the macrophages. Pentamidine 26-28 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 85-90 1337631-0 1992 Pentamidine: a non-peptide GPIIb/IIIa antagonist--in vitro studies on platelets from humans and other species. Pentamidine 0-11 integrin subunit alpha 2b Homo sapiens 27-32 8094333-9 1993 CONCLUSION: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3. Pentamidine 31-42 CD4 molecule Homo sapiens 102-105 8103731-4 1993 This diamidine has shown to be a competitive inhibitor of porcine kidney diamine oxidase with a Ki value of 13 microM. Pentamidine 5-14 amine oxidase copper containing 1 Homo sapiens 73-88 1337631-1 1992 In this paper we show that the non-peptide anti-parasite agent pentamidine is a broad spectrum anti-platelet agent with an IC50 of 1.1 microM in ADP-induced platelet aggregation in human platelet rich plasma (PRP). Pentamidine 63-74 proline rich protein HaeIII subfamily 1 Mus musculus 209-212 1337631-5 1992 Pentamidine showed a high degree of species selectivity with slightly less activity in monkey and dog PRP and little activity in guinea pig, rabbit, rat and mouse PRP compared with human. Pentamidine 0-11 proline rich protein HaeIII subfamily 1 Mus musculus 102-105 1337631-5 1992 Pentamidine showed a high degree of species selectivity with slightly less activity in monkey and dog PRP and little activity in guinea pig, rabbit, rat and mouse PRP compared with human. Pentamidine 0-11 proline rich protein HaeIII subfamily 1 Mus musculus 163-166 1337631-8 1992 Thus, pentamidine is a potent non-peptide inhibitor of fibrinogen binding to GPIIb/IIIa. Pentamidine 6-17 integrin subunit alpha 2b Homo sapiens 77-82 1370962-8 1992 In the case-control analysis, pentamidine isethionate was significantly associated with pancreatitis (p = 0.02); the risk was greater in patients who received pentamidine isethionate and had absolute CD4 T-lymphocyte counts less than 100 cells/mm3 (p = 0.001). Pentamidine 30-53 CD4 molecule Homo sapiens 200-203 1510731-1 1992 Pentamidine and berenil, clinical antiparasitic amidines, have been found to be potent competitive inhibitors of human spermidine/spermine acetyltransferase (SSAT). Pentamidine 0-11 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 119-156 1510731-1 1992 Pentamidine and berenil, clinical antiparasitic amidines, have been found to be potent competitive inhibitors of human spermidine/spermine acetyltransferase (SSAT). Pentamidine 0-11 spermidine/spermine N1-acetyltransferase 1 Homo sapiens 158-162 1510731-3 1992 A second enzyme of polyamine back-conversion, murine polyamine oxidase (PAO), was found to be competitively inhibited by pentamidine, with a Ki of 7.6 microM when N-acetylspermine was the substrate. Pentamidine 121-132 polyamine oxidase (exo-N4-amino) Mus musculus 53-70 1510731-3 1992 A second enzyme of polyamine back-conversion, murine polyamine oxidase (PAO), was found to be competitively inhibited by pentamidine, with a Ki of 7.6 microM when N-acetylspermine was the substrate. Pentamidine 121-132 polyamine oxidase (exo-N4-amino) Mus musculus 72-75 1293048-2 1992 Pentamidine aerosol was administered with an MA2 jet nebulizer. Pentamidine 0-11 PNMA family member 2 Homo sapiens 45-48 1623582-2 1992 Pentamidine is first extracted from serum by passage through a C-18 extraction cartridge. Pentamidine 0-11 Bardet-Biedl syndrome 9 Homo sapiens 63-67 1370962-13 1992 We conclude that pancreatitis is common in pediatric patients with AIDS and may be related to pentamidine isethionate exposure, especially when absolute CD4 T-lymphocyte counts are less than 100 cells/mm3. Pentamidine 94-117 CD4 molecule Homo sapiens 153-156 1662952-4 1991 Here we demonstrate that, very surprisingly, the addition of pentamidine (and to a lesser extent amiloride) to isolated hepatocytes results in an inhibition of the catalytic subunit of glucose-6-phosphatase. Pentamidine 61-72 glucose-6-phosphatase catalytic subunit 1 Homo sapiens 185-206 1539159-8 1992 In addition to decreased serum concentrations of cytokines, lungs isolated from mice treated with both pentamidine and endotoxin exhibited a decreased release of TNF compared to lungs isolated from mice treated with vehicle and endotoxin. Pentamidine 103-114 tumor necrosis factor Mus musculus 162-165 1539159-9 1992 The lower levels of TNF released from lung tissue in pentamidine-treated mice correlated with a lesser degree of alveolar deterioration than was observed in vehicle-treated mice. Pentamidine 53-64 tumor necrosis factor Mus musculus 20-23 2058040-6 1991 Therefore, inhalations of pentamidine twice monthly, as a primary prophylaxis against PCP, can be recommended in HIV-positive patients with CD4-cell counts below this level. Pentamidine 26-37 CD4 molecule Homo sapiens 140-143 1650253-0 1991 Pentamidine activates T1 the hepatic microsomal glucose 6-phosphate transport protein of the glucose-6-phosphatase system. Pentamidine 0-11 glucose-6-phosphatase catalytic subunit 1 Homo sapiens 93-114 1650253-1 1991 The mechanism of activation of hepatic microsomal glucose-6-phosphatase (EC 3.1.3.9) in vitro by pentamidine has been investigated in both intact and fully disrupted microsomes. Pentamidine 97-108 glucose-6-phosphatase catalytic subunit 1 Homo sapiens 50-71 1650253-2 1991 The major effect of pentamidine is a 4.7-fold reduction in the Km of glucose-6-phosphatase activity in intact diabetic rat liver microsomes. Pentamidine 20-31 glucose-6-phosphatase catalytic subunit 1 Rattus norvegicus 69-90 2005586-7 1991 Therefore, the mixed-function oxidases readily convert pentamidine to hydroxylated metabolites, but exactly which isozyme(s) of cytochrome P-450 is responsible is not clear. Pentamidine 55-66 cytochrome P450, family 2, subfamily g, polypeptide 1 Rattus norvegicus 128-144 1859238-0 1991 [Transitory acute kidney insufficiency and insulin-dependent after treatment of kala-azar with pentamidine and N-methylglucamine antimony]. Pentamidine 95-106 insulin Homo sapiens 43-50 1814681-2 1991 Three bisguanidine compounds (those of pentamidine, streptidine and phenformin) were compared for their in vitro inhibitory capacity on diamine oxidase activity (EC 1.4.3.6), the first enzyme of putrescine degradation. Pentamidine 39-50 amine oxidase copper containing 1 Homo sapiens 136-151 34948360-2 2021 A direct correlation between the increased amount of S100B and inflammatory processes has been demonstrated, and in particular, the inhibitor of S100B activity pentamidine has been shown to ameliorate clinical scores and neuropathologic-biomolecular parameters in the relapsing-remitting experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Pentamidine 160-171 S100 protein, beta polypeptide, neural Mus musculus 53-58 2142750-0 1990 [Preventive pentamidine inhalation in patients with HIV infection (CD3 and CD4) in ambulatory practice]. Pentamidine 12-23 CD4 molecule Homo sapiens 75-78 1814681-0 1991 Inhibition of diamine oxidase from porcine kidney by pentamidine and other aminoguanidine compounds. Pentamidine 53-64 amine oxidase copper containing 1 Homo sapiens 14-29 34948360-2 2021 A direct correlation between the increased amount of S100B and inflammatory processes has been demonstrated, and in particular, the inhibitor of S100B activity pentamidine has been shown to ameliorate clinical scores and neuropathologic-biomolecular parameters in the relapsing-remitting experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Pentamidine 160-171 S100 protein, beta polypeptide, neural Mus musculus 145-150 34234416-0 2021 Pentamidine Inhibits Ovarian Cancer Cell Proliferation and Migration by Maintaining Stability of PTEN in vitro. Pentamidine 0-11 phosphatase and tensin homolog Homo sapiens 97-101 34766746-3 2021 We here report the design, synthesis, and evaluation of a broader panel of bis-amidines inspired by pentamidine. Pentamidine 100-111 Bis protein Escherichia coli 75-78 34766746-5 2021 Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. Pentamidine 106-117 Bis protein Escherichia coli 10-13 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 S100 protein, beta polypeptide, neural Mus musculus 14-19 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 1 alpha Mus musculus 60-68 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 18 Mus musculus 70-75 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 6 Mus musculus 77-81 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 83-88 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 tumor necrosis factor Mus musculus 90-99 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 17A Mus musculus 101-106 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 23, alpha subunit p19 Mus musculus 108-113 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 interleukin 2 Mus musculus 119-123 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 suppressor of cytokine signaling 2 Mus musculus 208-213 34568098-7 2021 Inhibition of S100B by pentamidine reduced the synthesis of IL-1beta, IL-18, IL-6, GMCSF, TNF-alpha, IL-17, IL-23, and IL-2 and downregulated a variety of NFkappaB-related genes, increased the transcription (SOCS2 and Bcl-2) of protective mediators, reduced neutrophil recruitment, and ameliorated intestinal damage and diarrhea severity in mice. Pentamidine 23-34 B cell leukemia/lymphoma 2 Mus musculus 218-223 34234416-9 2021 Further investigation found that pentamidine increased the protein expression of PTEN and reduced phosphorylation levels of AKT in OC cells. Pentamidine 33-44 phosphatase and tensin homolog Homo sapiens 81-85 34234416-9 2021 Further investigation found that pentamidine increased the protein expression of PTEN and reduced phosphorylation levels of AKT in OC cells. Pentamidine 33-44 AKT serine/threonine kinase 1 Homo sapiens 124-127 34234416-10 2021 Pentamidine treatment modulated PTEN stability through the ubiquitin/proteasome pathway. Pentamidine 0-11 phosphatase and tensin homolog Homo sapiens 32-36 34234416-11 2021 In addition, pentamidine inhibited the expression of N-cadherin and snail, and increased E-cadherin expression in a dose-dependent manner. Pentamidine 13-24 cadherin 2 Homo sapiens 53-63 34234416-11 2021 In addition, pentamidine inhibited the expression of N-cadherin and snail, and increased E-cadherin expression in a dose-dependent manner. Pentamidine 13-24 snail family transcriptional repressor 1 Homo sapiens 68-73 34234416-11 2021 In addition, pentamidine inhibited the expression of N-cadherin and snail, and increased E-cadherin expression in a dose-dependent manner. Pentamidine 13-24 cadherin 1 Homo sapiens 89-99 34234416-12 2021 Conclusion: Pentamidine is involved in the maintenance of PTEN protein stability and suppresses proliferation and migration of OC cells. Pentamidine 12-23 phosphatase and tensin homolog Homo sapiens 58-62 35281916-0 2022 Pentamidine Alleviates Inflammation and Lipopolysaccharide-Induced Sepsis by Inhibiting TLR4 Activation via Targeting MD2. Pentamidine 0-11 toll-like receptor 4 Mus musculus 88-92 35620168-3 2022 We examined the relevance of S100B and further investigated the potential of S100B-neutralizing small-molecule pentamidine in chronic experimental autoimmune encephalomyelitis. Pentamidine 111-122 S100 calcium binding protein B Homo sapiens 77-82 35620168-6 2022 Blockade of S100B by pentamidine protects against oligodendrogenesis impairment and neuroinflammation by reducing astrocyte reactivity and microglia pro-inflammatory phenotype. Pentamidine 21-32 S100 calcium binding protein B Homo sapiens 12-17 35356785-15 2022 Pentamidine resistance is due to loss of mitochondria transport proteins P2 and HAPT1. Pentamidine 0-11 lysophospholipase 1 Homo sapiens 80-85 35281916-6 2022 Cellular thermal shift assay (CETSA) showed that pentamidine binding decreased MD2 stability, which was supported by in silico simulations that pentamidine binding rendered most regions of MD2 more flexible. Pentamidine 144-155 lymphocyte antigen 96 Mus musculus 79-82 35281916-6 2022 Cellular thermal shift assay (CETSA) showed that pentamidine binding decreased MD2 stability, which was supported by in silico simulations that pentamidine binding rendered most regions of MD2 more flexible. Pentamidine 144-155 lymphocyte antigen 96 Mus musculus 189-192 35281916-0 2022 Pentamidine Alleviates Inflammation and Lipopolysaccharide-Induced Sepsis by Inhibiting TLR4 Activation via Targeting MD2. Pentamidine 0-11 lymphocyte antigen 96 Mus musculus 118-121 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 toll-like receptor 4 Mus musculus 54-58 35281916-4 2022 In this study, pentamidine, an approved drug used in the treatment of trypanosomiasis, was identified as a TLR4 antagonist. Pentamidine 15-26 toll-like receptor 4 Mus musculus 107-111 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 lymphocyte antigen 96 Mus musculus 59-62 35281916-5 2022 Saturation transferred difference (STD)-NMR spectra indicated that pentamidine directly interacted with TLR4"s co-receptor myeloid differentiation protein 2 (MD2) in vitro. Pentamidine 67-78 toll-like receptor 4 Mus musculus 104-108 35281916-5 2022 Saturation transferred difference (STD)-NMR spectra indicated that pentamidine directly interacted with TLR4"s co-receptor myeloid differentiation protein 2 (MD2) in vitro. Pentamidine 67-78 lymphocyte antigen 96 Mus musculus 123-156 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 myeloid differentiation primary response gene 88 Mus musculus 63-68 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 toll-like receptor 4 Mus musculus 103-107 35281916-5 2022 Saturation transferred difference (STD)-NMR spectra indicated that pentamidine directly interacted with TLR4"s co-receptor myeloid differentiation protein 2 (MD2) in vitro. Pentamidine 67-78 lymphocyte antigen 96 Mus musculus 158-161 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 126-135 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 toll-like receptor 4 Mus musculus 178-182 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 tumor necrosis factor Mus musculus 240-249 35281916-7 2022 Pentamidine was found to inhibit the formation of the TLR4/MD2/MyD88 complex and the activation of the TLR4 signaling axes of NF-kappaB and MAPKs, therefore blocking LPS-induced TLR4 signaling downstream of the pro-inflammatory factors NO, TNF-alpha, and IL-1beta. Pentamidine 0-11 interleukin 1 alpha Mus musculus 255-263 35281916-8 2022 The bioisosteric replacement of the methylene group at the center 13" site of pentamidine by the ether oxygen group significantly decreased its interactions with MD2 and abolished its TLR4 antagonist activity. Pentamidine 78-89 lymphocyte antigen 96 Mus musculus 162-165 35281916-8 2022 The bioisosteric replacement of the methylene group at the center 13" site of pentamidine by the ether oxygen group significantly decreased its interactions with MD2 and abolished its TLR4 antagonist activity. Pentamidine 78-89 toll-like receptor 4 Mus musculus 184-188 35281916-6 2022 Cellular thermal shift assay (CETSA) showed that pentamidine binding decreased MD2 stability, which was supported by in silico simulations that pentamidine binding rendered most regions of MD2 more flexible. Pentamidine 49-60 lymphocyte antigen 96 Mus musculus 79-82 35281916-6 2022 Cellular thermal shift assay (CETSA) showed that pentamidine binding decreased MD2 stability, which was supported by in silico simulations that pentamidine binding rendered most regions of MD2 more flexible. Pentamidine 49-60 lymphocyte antigen 96 Mus musculus 189-192 2784286-0 1989 Insulin-dependent diabetes mellitus associated with pentamidine. Pentamidine 52-63 insulin Homo sapiens 0-7 2784286-1 1989 Insulin-dependent diabetes mellitus occurred following intravenous pentamidine treatment of two AIDS patients with Pneumocystis carinii pneumonia. Pentamidine 67-78 insulin Homo sapiens 0-7 6331162-11 1984 At 30 minutes, pentamidine alone caused passive release of immunoreactive insulin, 23 percent higher than control (p less than 0.01). Pentamidine 15-26 insulin Homo sapiens 74-81 3115268-0 1987 Inhibition of diamine oxidase of rat small intestine by pentamidine and berenil (diminazene aceturate). Pentamidine 56-67 amine oxidase, copper containing 1 Rattus norvegicus 14-29 3159693-4 1985 At concentrations of 1 microgram/ml (1.7 x 10(-6) M), pentamidine markedly inhibited the response to the B cell mitogen, lipopolysaccharide (LPS), while concentrations of 10 micrograms/ml had to be attained to produce a similar effect on the response to the T cell mitogens phytohaemagglutinin (PHA) and concanavalin A (ConA). Pentamidine 54-65 toll-like receptor 4 Mus musculus 141-144 3197257-2 1988 Pentamidine treatment appeared in the CSF. Pentamidine 0-11 granulocyte-macrophage colony-stimulating factor Ovis aries 38-41 3800910-5 1986 brucei AdoMet decarboxylase activity was apparently irreversibly inhibited in vitro by Berenil and reversibly by pentamidine and methylglyoxal bis(guanylhydrazone). Pentamidine 113-124 methionine adenosyltransferase 1A Rattus norvegicus 7-13 6331162-16 1984 At 72 hours, pentamidine suppressed immunoreactive insulin by 100 percent in all the media, irrespective of the presence or absence of stimulatory medium and/or chloroquine. Pentamidine 13-24 insulin Homo sapiens 51-58 6331162-17 1984 At the end of three weeks, there was 50 percent suppression of immunoreactive insulin in the control medium, but pentamidine again completely suppressed immunoreactive insulin. Pentamidine 113-124 insulin Homo sapiens 168-175 6331162-20 1984 However, when used in an in vitro monolayer system, pentamidine caused (1) acute immunoreactive insulin release followed by inhibition of immunoreactive insulin secretion and (2) cytolysis of human malignant insulinoma cells in vitro. Pentamidine 52-63 insulin Homo sapiens 96-103 6337258-1 1983 Thirteen serine proteinase inhibitors of the guanidine, monoamidine and diamidine type were tested for their ability to inhibit the proteinase acrosin present in the acrosome of ejaculated and capacitated boar spermatozoa. Pentamidine 72-81 acrosin Homo sapiens 143-150 6371261-2 1984 We observed inappropriately elevated insulin levels in a patient with Pneumocystis carinii pneumonia and pentamidine-induced hypoglycaemia. Pentamidine 105-116 insulin Homo sapiens 37-44 6371261-4 1984 Pentamidine may exert its hypoglycaemic effect by stimulating insulin secretion from the pancreas. Pentamidine 0-11 insulin Homo sapiens 62-69 6337258-4 1983 The intra-acrosomal inhibition of acrosin was assessed by the gelatin substrate film method: 2 guanidinobenzoates, one monoamidine and one diamidine derivative proved to inhibit acrosin completely in intact spermatozoa. Pentamidine 139-148 acrosin Homo sapiens 34-41 6337258-4 1983 The intra-acrosomal inhibition of acrosin was assessed by the gelatin substrate film method: 2 guanidinobenzoates, one monoamidine and one diamidine derivative proved to inhibit acrosin completely in intact spermatozoa. Pentamidine 139-148 acrosin Homo sapiens 178-185 6759211-10 1982 In vitro incubation of islets with pentamidine 10(-10) M produced a passive release of insulin, followed by a significant decrease in B-cell response to glucose + theophylline. Pentamidine 35-46 insulin Homo sapiens 87-94 6759211-11 1982 It is suggested that pentamidine can induce hypoglycemia because of an early cytolytic release of insulin, and then diabetes mellitus because of B-cell destruction and insulin deficiency. Pentamidine 21-32 insulin Homo sapiens 98-105 19999737-2 1973 Diamidines consisting of two amidinophenyl residues linked in para position by a molecular bridge proved to be the strongest competitive inhibitors of C1s, whereas those linked in meta position were the strongest competitive inhibitors of C1r. Pentamidine 0-10 complement C1s Homo sapiens 151-154 6989016-2 1980 Inhibition of factor Xa by diamidines. Pentamidine 27-37 coagulation factor X Homo sapiens 14-23 19999737-2 1973 Diamidines consisting of two amidinophenyl residues linked in para position by a molecular bridge proved to be the strongest competitive inhibitors of C1s, whereas those linked in meta position were the strongest competitive inhibitors of C1r. Pentamidine 0-10 complement C1r Homo sapiens 239-242 33923162-4 2021 Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. Pentamidine 167-178 S100 calcium binding protein P Homo sapiens 120-125 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 28-39 tumor protein p53 Homo sapiens 129-132 33923162-3 2021 We used 1H-15N HSQC experiments and molecular modeling to study the molecular interactions between S100P and p53 in the presence and absence of pentamidine. Pentamidine 144-155 S100 calcium binding protein P Homo sapiens 99-104 33923162-4 2021 Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. Pentamidine 101-112 S100 calcium binding protein P Homo sapiens 45-50 33923162-4 2021 Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. Pentamidine 101-112 S100 calcium binding protein P Homo sapiens 120-125 33923162-4 2021 Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. Pentamidine 101-112 tumor protein p53 Homo sapiens 159-162 33923162-4 2021 Our experimental analysis indicates that the S100P-53 complex formation is successfully disrupted by pentamidine, since S100P shares the same binding site for p53 and pentamidine. Pentamidine 167-178 S100 calcium binding protein P Homo sapiens 45-50 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 28-39 H3 histone pseudogene 16 Homo sapiens 137-140 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 28-39 S100 calcium binding protein P Homo sapiens 237-242 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 28-39 tumor protein p53 Homo sapiens 243-246 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 28-39 tumor protein p53 Homo sapiens 243-246 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 173-184 tumor protein p53 Homo sapiens 129-132 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 173-184 H3 histone pseudogene 16 Homo sapiens 137-140 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 173-184 S100 calcium binding protein P Homo sapiens 237-242 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 173-184 tumor protein p53 Homo sapiens 243-246 33923162-5 2021 In addition, we showed that pentamidine treatment of ZR-75-1 breast cancer cells resulted in reduced proliferation and increased p53 and p21 protein levels, indicating that pentamidine is an effective antagonist that interferes with the S100P-p53 interaction, leading to re-activation of the p53-21 pathway and inhibition of cancer cell proliferation. Pentamidine 173-184 tumor protein p53 Homo sapiens 243-246 33923162-6 2021 Collectively, our findings suggest that blocking the association between S100P and p53 by pentamidine will prevent cancer progression and, therefore, provide a new avenue for cancer therapy by targeting the S100P-p53 interaction. Pentamidine 90-101 S100 calcium binding protein P Homo sapiens 73-78 33923162-6 2021 Collectively, our findings suggest that blocking the association between S100P and p53 by pentamidine will prevent cancer progression and, therefore, provide a new avenue for cancer therapy by targeting the S100P-p53 interaction. Pentamidine 90-101 tumor protein p53 Homo sapiens 83-86 33923162-6 2021 Collectively, our findings suggest that blocking the association between S100P and p53 by pentamidine will prevent cancer progression and, therefore, provide a new avenue for cancer therapy by targeting the S100P-p53 interaction. Pentamidine 90-101 S100 calcium binding protein P Homo sapiens 207-212 33923162-6 2021 Collectively, our findings suggest that blocking the association between S100P and p53 by pentamidine will prevent cancer progression and, therefore, provide a new avenue for cancer therapy by targeting the S100P-p53 interaction. Pentamidine 90-101 tumor protein p53 Homo sapiens 213-216 33550183-3 2021 In this study, the interactions of the transmembrane domain 5 (TMD-5) of latent membrane protein 1 (LMP-1) of Epstein-Barr virus (EBV) were disrupted by pentamidine derivatives to curb the committed step of EBV infection. Pentamidine 153-164 PDZ and LIM domain 7 Homo sapiens 100-105 32649952-6 2020 Our results suggest that the p53 TAD and pentamidine molecules share similar binding sites on the S100A4 protein. Pentamidine 41-52 S100 calcium binding protein A4 Homo sapiens 98-104 32649952-0 2020 Pentamidine inhibit S100A4 - p53 interaction and decreases cell proliferation activity. Pentamidine 0-11 S100 calcium binding protein A4 Homo sapiens 20-26 32649952-9 2020 We found that the presence of a pentamidine molecule results in higher p53 activity, which is also reflected in less cell proliferation. Pentamidine 32-43 tumor protein p53 Homo sapiens 71-74 32649952-0 2020 Pentamidine inhibit S100A4 - p53 interaction and decreases cell proliferation activity. Pentamidine 0-11 tumor protein p53 Homo sapiens 29-32 34046601-3 2021 Based on the previously reported PRMT1 inhibitors bearing the diamidine pharmacophore, we performed virtual screening to identify additional amidine-associated structural analogs. Pentamidine 62-71 protein arginine methyltransferase 1 Homo sapiens 33-38 32649952-5 2020 In the current study, based on 1H-15N HSQC NMR experiments and HADDOCK results, S100A4 interacts with the intrinsically unstructured transactivation domain (TAD) of the protein p53 and the pentamidine molecules in the presence of calcium ions. Pentamidine 189-200 S100 calcium binding protein A4 Homo sapiens 80-86 32197530-0 2020 The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing-Remitting Multiple Sclerosis Mouse Model. Pentamidine 20-31 S100 protein, beta polypeptide, neural Mus musculus 4-9 32415090-7 2020 Furthermore, a diamidine class of PRMT1 inhibitors exhibited anti-neuroblastoma efficacy both in vitro and in vivo. Pentamidine 15-24 protein arginine methyltransferase 1 Homo sapiens 34-39 32505874-9 2020 Renal function temporary worsened and addition of insulin was required due to maintain glycemic compensation also after pentamidine discontinuation. Pentamidine 120-131 insulin Homo sapiens 50-57 32334013-6 2020 Pentamidine (OCT1/OCT2 inhibitor) decreased apical transport (P = 0.001) while atropine (OCT1 inhibitor) had no effect, suggesting apical transport involved OCT2. Pentamidine 0-11 solute carrier family 22 member 1 Homo sapiens 13-17 32334013-6 2020 Pentamidine (OCT1/OCT2 inhibitor) decreased apical transport (P = 0.001) while atropine (OCT1 inhibitor) had no effect, suggesting apical transport involved OCT2. Pentamidine 0-11 solute carrier family 22 member 2 Homo sapiens 18-22 32334013-6 2020 Pentamidine (OCT1/OCT2 inhibitor) decreased apical transport (P = 0.001) while atropine (OCT1 inhibitor) had no effect, suggesting apical transport involved OCT2. Pentamidine 0-11 solute carrier family 22 member 2 Homo sapiens 157-161 32241959-3 2020 Many drugs, like pentamidine, interfere with normal Kv11.1 forward trafficking and thus reduce functional Kv11.1 channel densities. Pentamidine 17-28 potassium voltage-gated channel modifier subfamily V member 2 Homo sapiens 52-58 32241959-3 2020 Many drugs, like pentamidine, interfere with normal Kv11.1 forward trafficking and thus reduce functional Kv11.1 channel densities. Pentamidine 17-28 potassium voltage-gated channel modifier subfamily V member 2 Homo sapiens 106-112 32241959-7 2020 Pentamidine-decreased maturation of WT Kv11.1 levels was rescued by 10 muM dofetilide or 10 muM dofetilide + 5 muM LUF7244. Pentamidine 0-11 potassium voltage-gated channel modifier subfamily V member 2 Homo sapiens 39-45 32197530-3 2020 The aim of this study is to investigate the possible role of a small molecule able to bind and inhibit S100B, pentamidine, in the modulation of disease progression in the relapsing-remitting experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Pentamidine 110-121 S100 protein, beta polypeptide, neural Mus musculus 103-108 32197530-7 2020 Overall, our results indicate that pentamidine targeting the S100B protein is a novel potential drug to be considered for multiple sclerosis treatment. Pentamidine 35-46 S100 protein, beta polypeptide, neural Mus musculus 61-66 32022398-0 2020 Pentamidine niosomes thwart S100B effects in human colon carcinoma biopsies favouring wtp53 rescue. Pentamidine 0-11 S100 calcium binding protein B Homo sapiens 28-33 32022398-2 2020 Being an S100B inhibitor, pentamidine antagonizes S100B-wtp53 interaction, restoring wtp53-mediated pro-apoptotic control in cancer cells in several types of tumours. Pentamidine 26-37 S100 calcium binding protein B Homo sapiens 9-14 32022398-2 2020 Being an S100B inhibitor, pentamidine antagonizes S100B-wtp53 interaction, restoring wtp53-mediated pro-apoptotic control in cancer cells in several types of tumours. Pentamidine 26-37 S100 calcium binding protein B Homo sapiens 50-55 31331643-0 2019 Pentamidine protects mice from cecal ligation and puncture-induced brain damage via inhibiting S100B/RAGE/NF-kappaB. Pentamidine 0-11 MOK protein kinase Mus musculus 101-105 31007068-4 2019 Cytotoxicity was tested against the immortalized mouse brain endothelioma cells over 96 h. Moreover, cells monolayer integrity and transportation ability were examined for 24 h. Pentamidine-loaded polycaprolactone (PCL) nanoparticles had a mean size of 267.58, PDI of 0.25 and zeta potential of -28.1 mV and pentamidine-loaded liposomes had a mean size of 119.61 nm, PDI of 0.25 and zeta potential 11.78. Pentamidine 178-189 peptidyl arginine deiminase 1 Homo sapiens 261-264 31007068-4 2019 Cytotoxicity was tested against the immortalized mouse brain endothelioma cells over 96 h. Moreover, cells monolayer integrity and transportation ability were examined for 24 h. Pentamidine-loaded polycaprolactone (PCL) nanoparticles had a mean size of 267.58, PDI of 0.25 and zeta potential of -28.1 mV and pentamidine-loaded liposomes had a mean size of 119.61 nm, PDI of 0.25 and zeta potential 11.78. Pentamidine 178-189 peptidyl arginine deiminase 1 Homo sapiens 367-370 31331643-0 2019 Pentamidine protects mice from cecal ligation and puncture-induced brain damage via inhibiting S100B/RAGE/NF-kappaB. Pentamidine 0-11 S100 protein, beta polypeptide, neural Mus musculus 95-100 31331643-0 2019 Pentamidine protects mice from cecal ligation and puncture-induced brain damage via inhibiting S100B/RAGE/NF-kappaB. Pentamidine 0-11 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 106-115 31331643-3 2019 In this study, we demonstrated that pentamidine, an antiprotozoal drug, is a good candidate since it blocks S100B/RAGE/NF-kappaB signaling pathway. Pentamidine 36-47 S100 protein, beta polypeptide, neural Mus musculus 108-113 31331643-3 2019 In this study, we demonstrated that pentamidine, an antiprotozoal drug, is a good candidate since it blocks S100B/RAGE/NF-kappaB signaling pathway. Pentamidine 36-47 MOK protein kinase Mus musculus 114-118 31331643-3 2019 In this study, we demonstrated that pentamidine, an antiprotozoal drug, is a good candidate since it blocks S100B/RAGE/NF-kappaB signaling pathway. Pentamidine 36-47 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 119-128 31331643-6 2019 Immunofluorescence and Western blot analysis also showed that pentamidine inhibited CLP-induced gliosis and S100B/RAGE/NF-kappaB pathway activation. Pentamidine 62-73 S100 protein, beta polypeptide, neural Mus musculus 108-113 31331643-6 2019 Immunofluorescence and Western blot analysis also showed that pentamidine inhibited CLP-induced gliosis and S100B/RAGE/NF-kappaB pathway activation. Pentamidine 62-73 MOK protein kinase Mus musculus 114-118 31331643-6 2019 Immunofluorescence and Western blot analysis also showed that pentamidine inhibited CLP-induced gliosis and S100B/RAGE/NF-kappaB pathway activation. Pentamidine 62-73 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 119-128 31174390-5 2019 Using normal plasma, pentamidine isethionate doubled the activated partial thromboplastin time at 27.5 microM, doubled the prothrombin time at 45.7 microM, and weakly doubled the thrombin time at 158.17 microM. Pentamidine 21-44 coagulation factor II, thrombin Homo sapiens 126-134 31174390-7 2019 Pentamidine also inhibited plasmin-mediated clot lysis with half-maximal inhibitory concentration (IC50) value of ~3.6 muM. Pentamidine 0-11 plasminogen Homo sapiens 27-34 31174390-8 2019 Chromogenic substrate hydrolysis assays indicated that pentamidine inhibits factor Xa and plasmin with IC50 values of 10.4 microM and 8.4 microM, respectively. Pentamidine 55-66 coagulation factor X Homo sapiens 76-85 31174390-8 2019 Chromogenic substrate hydrolysis assays indicated that pentamidine inhibits factor Xa and plasmin with IC50 values of 10.4 microM and 8.4 microM, respectively. Pentamidine 55-66 plasminogen Homo sapiens 90-97 31174390-10 2019 Michaelis-Menten kinetics and molecular modeling studies revealed that pentamidine inhibits factor Xa and plasmin in a competitive fashion. Pentamidine 71-82 coagulation factor X Homo sapiens 92-101 31174390-10 2019 Michaelis-Menten kinetics and molecular modeling studies revealed that pentamidine inhibits factor Xa and plasmin in a competitive fashion. Pentamidine 71-82 plasminogen Homo sapiens 106-113 31174390-11 2019 Overall, this study provides quantitative mechanistic insights into the in vitro effects of pentamidine isethionate on coagulation and fibrinolysis via the disruption of the proteolytic activity of factor Xa and plasmin. Pentamidine 92-115 coagulation factor X Homo sapiens 198-207 31174390-11 2019 Overall, this study provides quantitative mechanistic insights into the in vitro effects of pentamidine isethionate on coagulation and fibrinolysis via the disruption of the proteolytic activity of factor Xa and plasmin. Pentamidine 92-115 plasminogen Homo sapiens 212-219 31213240-11 2019 As pentamidine and diminazene have been reported to be potent inhibitors of mammalian acid-sensing ion channels (ASIC), we tested the activity of known ASIC inhibitors against H. contortus to probe whether these channels may represent potential anthelmintic targets in nematodes. Pentamidine 3-14 acid sensing ion channel subunit 1 Homo sapiens 86-111 31213240-11 2019 As pentamidine and diminazene have been reported to be potent inhibitors of mammalian acid-sensing ion channels (ASIC), we tested the activity of known ASIC inhibitors against H. contortus to probe whether these channels may represent potential anthelmintic targets in nematodes. Pentamidine 3-14 acid sensing ion channel subunit 1 Homo sapiens 113-117 30529726-2 2019 Pentamidine, an old-developed antiprotozoal drug, currently used for pneumocystis carinii is one of the most potent inhibitors of S100B activity, but despite this effect, is limited by its low capability to cross blood brain barrier (BBB). Pentamidine 0-11 S100 protein, beta polypeptide, neural Mus musculus 130-135 30789910-0 2019 Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. Pentamidine 98-109 CD4 molecule Homo sapiens 144-147 30789910-5 2019 Patients with CD4 cell counts below 200/muL at the end of VL treatment received pentamidine prophylaxis starting one month after parasitological cure, while those with CD4 count >=200 cells/muL were followed without secondary prophylaxis. Pentamidine 80-91 CD4 molecule Homo sapiens 14-17 31205855-11 2019 Pentamidine also suppressed RANKL-induced osteoclast differentiation and actin ring formation markedly, and inhibited the expression of nuclear factor of activated T cell c1 and osteoclast-specific genes in vitro. Pentamidine 0-11 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 28-33 31205855-12 2019 Additionally, pentamidine also attenuated RANKL-mediated phosphorylation of IkappaBalpha in BMMs. Pentamidine 14-25 tumor necrosis factor (ligand) superfamily, member 11 Mus musculus 42-47 31205855-12 2019 Additionally, pentamidine also attenuated RANKL-mediated phosphorylation of IkappaBalpha in BMMs. Pentamidine 14-25 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 76-88 30789910-14 2019 Relapse-free survival of patients with CD4 count <200cells/muL given pentamidine secondary prophylaxis appeared to be comparable to patients with a CD4 count >=200 cells/muL not given prophylaxis. Pentamidine 72-83 CD4 molecule Homo sapiens 39-42 30789910-14 2019 Relapse-free survival of patients with CD4 count <200cells/muL given pentamidine secondary prophylaxis appeared to be comparable to patients with a CD4 count >=200 cells/muL not given prophylaxis. Pentamidine 72-83 tripartite motif containing 37 Homo sapiens 62-65 30645099-0 2019 Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model. Pentamidine 13-22 homeobox A9 Mus musculus 38-43 30645099-4 2019 As an attractive alternative by inhibiting the DNA binding, we selected a series of heterocyclic diamidines as efficient competitors for the HOXA9/DNA interaction through binding as minor groove DNA ligands on the HOXA9 cognate sequence. Pentamidine 97-107 homeobox A9 Mus musculus 141-146 30645099-4 2019 As an attractive alternative by inhibiting the DNA binding, we selected a series of heterocyclic diamidines as efficient competitors for the HOXA9/DNA interaction through binding as minor groove DNA ligands on the HOXA9 cognate sequence. Pentamidine 97-107 homeobox A9 Mus musculus 214-219 30679569-5 2019 We provide evidence that 5-FU induces reactive gliosis and reduction of enteric neurons in a S100B/RAGE/NFkappaB-dependent manner, since pentamidine, a S100B inhibitor, prevented 5-FU-induced neuronal loss, enteric glia activation, intestinal inflammation, oxidative stress and histological injury. Pentamidine 137-148 S100 calcium binding protein B Homo sapiens 93-98 30679569-5 2019 We provide evidence that 5-FU induces reactive gliosis and reduction of enteric neurons in a S100B/RAGE/NFkappaB-dependent manner, since pentamidine, a S100B inhibitor, prevented 5-FU-induced neuronal loss, enteric glia activation, intestinal inflammation, oxidative stress and histological injury. Pentamidine 137-148 advanced glycosylation end-product specific receptor Homo sapiens 99-103 30679569-5 2019 We provide evidence that 5-FU induces reactive gliosis and reduction of enteric neurons in a S100B/RAGE/NFkappaB-dependent manner, since pentamidine, a S100B inhibitor, prevented 5-FU-induced neuronal loss, enteric glia activation, intestinal inflammation, oxidative stress and histological injury. Pentamidine 137-148 nuclear factor kappa B subunit 1 Homo sapiens 104-112 30679569-5 2019 We provide evidence that 5-FU induces reactive gliosis and reduction of enteric neurons in a S100B/RAGE/NFkappaB-dependent manner, since pentamidine, a S100B inhibitor, prevented 5-FU-induced neuronal loss, enteric glia activation, intestinal inflammation, oxidative stress and histological injury. Pentamidine 137-148 S100 calcium binding protein B Homo sapiens 152-157 30061855-8 2018 Importantly, small molecules pentamidine and daunorubicin were able to rescue cardiac phenotypes by releasing Muscleblind from sequestration. Pentamidine 29-40 muscleblind Drosophila melanogaster 110-121 30391349-2 2019 Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. Pentamidine 0-11 ETS transcription factor ERG Homo sapiens 89-93 30391349-2 2019 Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. Pentamidine 0-11 heat shock protein 90 alpha family class A member 1 Homo sapiens 254-259 30391349-2 2019 Pentamidine, an antiprotozoal drug, causes QT prolongation/Torsades de Pointes (TdP) via hERG trafficking inhibition, but 17-AAG, a geldanamycin derivative heat shock protein 90 (Hsp90) inhibitor, has not shown torsadogenic potential clinically, despite Hsp90 inhibitors generally being hypothesized to cause TdP by hERG trafficking inhibition. Pentamidine 0-11 ETS transcription factor ERG Homo sapiens 316-320 30631059-6 2019 The suitability of the model for drug safety evaluation is exemplified by repeated assessment of refractory period that permits sensitive analysis of repolarization impairment induced by the multimodal hERG-inhibitor pentamidine. Pentamidine 217-228 ETS transcription factor ERG Homo sapiens 202-206 28358927-2 2017 For example, AQP2 in the human-infectious African trypanosome, Trypanosoma brucei gambiense, is responsible for melarsoprol and pentamidine-uptake, and melarsoprol treatment-failure has been found to be due to AQP2-defects in these parasites. Pentamidine 128-139 aquaporin 2 Homo sapiens 13-17 28888990-4 2017 We have screened chemical libraries and found that two antibiotics, pentamidine and clarithromycin, can compensate two bcs1 point mutations in yeast, one of which is the equivalent of a mutation found in a human patient. Pentamidine 68-79 bifunctional AAA family ATPase chaperone/translocase BCS1 Saccharomyces cerevisiae S288C 119-123 29083320-3 2017 These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. Pentamidine 42-51 spleen focus forming virus (SFFV) proviral integration oncogene Mus musculus 88-92 29083320-3 2017 These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. Pentamidine 42-51 spleen focus forming virus (SFFV) proviral integration oncogene Mus musculus 159-163 28396172-7 2017 The increase in TRAP was recapitulated by the potent and specific IK1 inhibitor, PA-6 (pentamidine analog 6), indicating that IK1 is the primary determinant of the final phase of repolarization. Pentamidine 87-98 acid phosphatase 5, tartrate resistant Sus scrofa 16-20 28711067-3 2017 Pentamidine-Analogue 6 (PA-6) is an efficient (IC50 = 14 nM with inside-out patch clamp methodology) and specific IK1 inhibitor that interacts with the cytoplasmic pore region of the KIR2.1 ion channel, encoded by KCNJ2. Pentamidine 0-11 IKAROS family zinc finger 1 Homo sapiens 114-117 28711067-3 2017 Pentamidine-Analogue 6 (PA-6) is an efficient (IC50 = 14 nM with inside-out patch clamp methodology) and specific IK1 inhibitor that interacts with the cytoplasmic pore region of the KIR2.1 ion channel, encoded by KCNJ2. Pentamidine 0-11 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 183-189 28711067-3 2017 Pentamidine-Analogue 6 (PA-6) is an efficient (IC50 = 14 nM with inside-out patch clamp methodology) and specific IK1 inhibitor that interacts with the cytoplasmic pore region of the KIR2.1 ion channel, encoded by KCNJ2. Pentamidine 0-11 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 214-219 28362799-0 2017 Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB). Pentamidine 51-62 solute carrier family 22 member 1 Homo sapiens 0-28 28362799-0 2017 Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB). Pentamidine 51-62 solute carrier family 22 member 1 Homo sapiens 30-34 28362799-11 2017 From the data, we conclude that pentamidine interacts with multiple transporters, is taken into brain endothelial cells by OCT1 transporter and is extruded into the blood by ATP-dependent mechanisms. Pentamidine 32-43 solute carrier family 22 member 1 Homo sapiens 123-127 28362799-12 2017 These interactions along with the predominant presence of OCT1 in the luminal membrane of the BBB contribute to the limited entry of pentamidine into the brain. Pentamidine 133-144 solute carrier family 22 member 1 Homo sapiens 58-62 29890625-5 2018 We investigated: 1. the occurrence of effective sensitization to PNT by analysing acute allergic skin response, anaphylactic symptoms score, body temperature, serum mucosal mast cell protease-1 (mMCP-1) and anti-PNT immunoglobulin E (IgE) levels; 2. hepatic involvement by analysing interleukin (IL)-4, IL-5, IL-13, IL-10 and IFN-&gamma; mRNA expression; 3. hepatic mitochondrial oxidation rates and efficiency by polarography, and hydrogen peroxide (H2O2) yield, aconitase and superoxide dysmutase activities by spectrophotometry. Pentamidine 65-68 interleukin 5 Mus musculus 303-307 29890625-5 2018 We investigated: 1. the occurrence of effective sensitization to PNT by analysing acute allergic skin response, anaphylactic symptoms score, body temperature, serum mucosal mast cell protease-1 (mMCP-1) and anti-PNT immunoglobulin E (IgE) levels; 2. hepatic involvement by analysing interleukin (IL)-4, IL-5, IL-13, IL-10 and IFN-&gamma; mRNA expression; 3. hepatic mitochondrial oxidation rates and efficiency by polarography, and hydrogen peroxide (H2O2) yield, aconitase and superoxide dysmutase activities by spectrophotometry. Pentamidine 65-68 interleukin 13 Mus musculus 309-314 29890625-5 2018 We investigated: 1. the occurrence of effective sensitization to PNT by analysing acute allergic skin response, anaphylactic symptoms score, body temperature, serum mucosal mast cell protease-1 (mMCP-1) and anti-PNT immunoglobulin E (IgE) levels; 2. hepatic involvement by analysing interleukin (IL)-4, IL-5, IL-13, IL-10 and IFN-&gamma; mRNA expression; 3. hepatic mitochondrial oxidation rates and efficiency by polarography, and hydrogen peroxide (H2O2) yield, aconitase and superoxide dysmutase activities by spectrophotometry. Pentamidine 65-68 interleukin 10 Mus musculus 316-321 29565809-7 2018 In particular, interactions with mucin were observed in both drug free and pentamidine loaded niosomes regardless of the presence of the coating. Pentamidine 75-86 LOC100508689 Homo sapiens 33-38 29565809-8 2018 The characteristics of the proposed systems, such as pentamidine entrapment and mucin interaction, show promising results to deliver pentamidine or other possible drugs to the brain via nasal administration. Pentamidine 133-144 LOC100508689 Homo sapiens 80-85 28993158-0 2017 High-potency block of Kir4.1 channels by pentamidine: Molecular basis. Pentamidine 41-52 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 22-28 28993158-5 2017 Here, we characterized the effect of pentamidine on Kir4.1 channels using electrophysiology, mutagenesis and computational methods. Pentamidine 37-48 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 52-58 28993158-6 2017 Pentamidine potently inhibited Kir4.1 channels when applied to the cytoplasmic side under inside-out patch clamp configuration (IC50 = 97nM). Pentamidine 0-11 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 31-37 28993158-8 2017 Molecular modeling predicted the binding of pentamidine to the transmembrane pore region of Kir4.1 at aminoacids T127, T128 and E158. Pentamidine 44-55 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 92-98 28993158-9 2017 Mutation of each of these residues reduced the potency of pentamidine to block Kir4.1 channels. Pentamidine 58-69 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 79-85 28993158-10 2017 A pentamidine analog (PA-6) inhibited Kir4.1 with similar potency (IC50 = 132nM). Pentamidine 2-13 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 38-44 28993158-11 2017 Overall, this study shows that pentamidine blocks Kir4.1 channels interacting with threonine and glutamate residues in the transmembrane pore region. Pentamidine 31-42 potassium inwardly rectifying channel subfamily J member 10 Homo sapiens 50-56 28542844-2 2017 The synthetic compound pentamidine analogue 6 (PA-6) is a selective and potent IK1 inhibitor. Pentamidine 23-34 IKAROS family zinc finger 1 Homo sapiens 79-82 28649316-3 2017 Herein, we reported the modification of a series of diamidine compounds with varied lengths in the middle alkyl linker for PRMT1 inhibition. Pentamidine 52-61 protein arginine methyltransferase 1 Homo sapiens 123-128 27084108-10 2016 A long-term study (over 30h) of pentamidine, a hERG trafficking inhibitor, showed a concentration and time-dependent effect of pentamidine. Pentamidine 32-43 ETS transcription factor ERG Homo sapiens 47-51 27084108-10 2016 A long-term study (over 30h) of pentamidine, a hERG trafficking inhibitor, showed a concentration and time-dependent effect of pentamidine. Pentamidine 127-138 ETS transcription factor ERG Homo sapiens 47-51 27282640-12 2016 In addition, pentamidine, a hERG trafficking inhibitor which induced irregular beating activity over a more prolonged duration of time was readily flagged in this assay system. Pentamidine 13-24 ETS transcription factor ERG Homo sapiens 28-32 27297108-0 2016 Pentamidine blocks the interaction between mutant S100A5 and RAGE V domain and inhibits the RAGE signaling pathway. Pentamidine 0-11 S100 calcium binding protein A5 Homo sapiens 50-56 27297108-0 2016 Pentamidine blocks the interaction between mutant S100A5 and RAGE V domain and inhibits the RAGE signaling pathway. Pentamidine 0-11 advanced glycosylation end-product specific receptor Homo sapiens 61-65 27297108-0 2016 Pentamidine blocks the interaction between mutant S100A5 and RAGE V domain and inhibits the RAGE signaling pathway. Pentamidine 0-11 advanced glycosylation end-product specific receptor Homo sapiens 92-96 27297108-6 2016 Here, we found that pentamidine interacts with S100A5 using HSQC titration. Pentamidine 20-31 S100 calcium binding protein A5 Homo sapiens 47-53 27297108-7 2016 We elucidated the interactions of S100A5 with RAGE V domain and pentamidine using fluorescence and NMR spectroscopy. Pentamidine 64-75 S100 calcium binding protein A5 Homo sapiens 34-40 27297108-8 2016 We generated two binary models-the S100A5-RAGE V domain and S100A5-Pentamidine complex-and then observed that the pentamidine and RAGE V domain share a similar binding region in mS100A5. Pentamidine 67-78 S100 calcium binding protein A5 Homo sapiens 60-66 27297108-10 2016 These results indicated that pentamidine blocks the binding between S100A5 and RAGE V domain. Pentamidine 29-40 S100 calcium binding protein A5 Homo sapiens 68-74 27297108-10 2016 These results indicated that pentamidine blocks the binding between S100A5 and RAGE V domain. Pentamidine 29-40 advanced glycosylation end-product specific receptor Homo sapiens 79-83 25814953-5 2015 A genome-wide RNAi library screen for resistance to pentamidine, published in 2012, gave the key to the genetic identity of HAPT1 by linking the phenomenon to a locus that contains the closely related T. brucei aquaglyceroporin genes TbAQP2 and TbAQP3. Pentamidine 52-63 lysophospholipase 1 Homo sapiens 124-129 26515653-8 2015 As a proof of concept that the fly heart model can be used for in vivo testing of promising therapeutic compounds, we fed flies with pentamidine, a compound previously described to improve DM1 phenotypes. Pentamidine 133-144 tarsal-less 1A Drosophila melanogaster 189-192 26515653-9 2015 Pentamidine not only released Muscleblind from the CUG RNA repeats and reduced ribonuclear formation in the Drosophila heart, but also rescued heart arrhythmicity and contractility, and improved fly survival in animals expressing 250 CUG repeats. Pentamidine 0-11 muscleblind Drosophila melanogaster 30-41 26137161-0 2015 S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Pentamidine 27-38 S100 calcium binding protein B Rattus norvegicus 0-5 26137161-0 2015 S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Pentamidine 27-38 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 6-9 26137161-0 2015 S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells. Pentamidine 27-38 aquaporin 4 Rattus norvegicus 94-105 26137161-2 2015 In melanoma cells, this S100B-p53 interaction is known to be inhibited by pentamidine isethionate, an antiprotozoal agent. Pentamidine 74-97 S100 calcium binding protein B Rattus norvegicus 24-29 26137161-2 2015 In melanoma cells, this S100B-p53 interaction is known to be inhibited by pentamidine isethionate, an antiprotozoal agent. Pentamidine 74-97 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 30-33 26727270-1 2016 The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100B p53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. Pentamidine 9-20 tumor protein p53 Homo sapiens 71-74 26727270-1 2016 The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100B p53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. Pentamidine 9-20 S100 calcium binding protein B Homo sapiens 80-85 26727270-1 2016 The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100B p53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. Pentamidine 9-20 tumor protein p53 Homo sapiens 86-89 26727270-1 2016 The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100B p53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. Pentamidine 9-20 tumor protein p53 Homo sapiens 86-89 26727270-3 2016 Structure-activity relationship (SAR) studies were therefore completed here with 23 pentamidine analogues, and X-ray structures of (Ca)S100B inhibitor complexes revealed that the C-terminus of S100B adopts two different conformations, with location of Phe87 and Phe88 being the distinguishing feature and termed the "FF-gate". Pentamidine 84-95 S100 calcium binding protein B Homo sapiens 193-198 26727270-4 2016 For symmetric pentamidine analogues ((Ca)S100B 5a, (Ca)S100B 6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B 17), this same channel was open. Pentamidine 14-25 S100 calcium binding protein B Homo sapiens 41-46 26727270-4 2016 For symmetric pentamidine analogues ((Ca)S100B 5a, (Ca)S100B 6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B 17), this same channel was open. Pentamidine 14-25 S100 calcium binding protein B Homo sapiens 55-60 26727270-4 2016 For symmetric pentamidine analogues ((Ca)S100B 5a, (Ca)S100B 6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B 17), this same channel was open. Pentamidine 14-25 S100 calcium binding protein B Homo sapiens 55-60 26727270-4 2016 For symmetric pentamidine analogues ((Ca)S100B 5a, (Ca)S100B 6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B 17), this same channel was open. Pentamidine 14-25 S100 calcium binding protein B Homo sapiens 55-60 26727270-5 2016 The (Ca)S100B 17 structure illustrates, for the first time, a pentamidine analog capable of binding the "open" form of the "FF-gate" and provides a means to block all three "hot spots" on (Ca)S100B, which will impact next generation (Ca)S100B p53 inhibitor design. Pentamidine 62-73 S100 calcium binding protein B Homo sapiens 8-13 26727270-5 2016 The (Ca)S100B 17 structure illustrates, for the first time, a pentamidine analog capable of binding the "open" form of the "FF-gate" and provides a means to block all three "hot spots" on (Ca)S100B, which will impact next generation (Ca)S100B p53 inhibitor design. Pentamidine 62-73 S100 calcium binding protein B Homo sapiens 192-197 26727270-5 2016 The (Ca)S100B 17 structure illustrates, for the first time, a pentamidine analog capable of binding the "open" form of the "FF-gate" and provides a means to block all three "hot spots" on (Ca)S100B, which will impact next generation (Ca)S100B p53 inhibitor design. Pentamidine 62-73 S100 calcium binding protein B Homo sapiens 192-197 26727270-5 2016 The (Ca)S100B 17 structure illustrates, for the first time, a pentamidine analog capable of binding the "open" form of the "FF-gate" and provides a means to block all three "hot spots" on (Ca)S100B, which will impact next generation (Ca)S100B p53 inhibitor design. Pentamidine 62-73 tumor protein p53 Homo sapiens 243-246 24307270-5 2014 Pentamidine, on the other hand, potently inhibits both MAO-A and MAO-B with IC50 values of 0.61 muM and 0.22 muM, respectively. Pentamidine 0-11 monoamine oxidase A Homo sapiens 55-60 25275572-12 2014 However, in all these strains, irrespective of the patient treatment outcome, the two aquaglyceroporin (AQP) 2 and 3 genes are replaced by chimeric AQP2/3 genes that may be associated with resistance to pentamidine and melarsoprol. Pentamidine 203-214 aquaporin 2 Homo sapiens 104-116 25275572-12 2014 However, in all these strains, irrespective of the patient treatment outcome, the two aquaglyceroporin (AQP) 2 and 3 genes are replaced by chimeric AQP2/3 genes that may be associated with resistance to pentamidine and melarsoprol. Pentamidine 203-214 aquaporin 2 Homo sapiens 148-154 25815158-3 2015 The diamidine inhibitor 7 binds to human FPPS close to the homoallylic (S2) and allosteric (S3) sites and extends into a new site, here called S4. Pentamidine 4-13 farnesyl diphosphate synthase Homo sapiens 41-45 25815158-6 2015 The diamidine structure is of particular interest because 7 could represent a new lead for lipophilic FPPS inhibitors, while 8 has low micromolar activity against T. brucei, the causative agent of human African trypanosomiasis. Pentamidine 4-13 farnesyl diphosphate synthase Homo sapiens 102-106 26295040-0 2015 S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer"s Disease. Pentamidine 16-27 S100 protein, beta polypeptide, neural Mus musculus 0-5 26295040-3 2015 The antiprotozoal drug pentamidine is a good candidate since it directly blocks S100B activity by inhibiting its interaction with the tumor suppressor p53. Pentamidine 23-34 S100 protein, beta polypeptide, neural Mus musculus 80-85 26295040-3 2015 The antiprotozoal drug pentamidine is a good candidate since it directly blocks S100B activity by inhibiting its interaction with the tumor suppressor p53. Pentamidine 23-34 transformation related protein 53, pseudogene Mus musculus 151-154 26295040-4 2015 We used a mouse model of amyloid beta- (Abeta-) induced AD, which is characterized by reactive gliosis and neuroinflammation in the brain, and we evaluated the effect of pentamidine on the main S100B-mediated events. Pentamidine 170-181 S100 protein, beta polypeptide, neural Mus musculus 194-199 26295040-5 2015 Pentamidine caused the reduction of glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in astrocytes. Pentamidine 0-11 glial fibrillary acidic protein Mus musculus 36-67 26295040-5 2015 Pentamidine caused the reduction of glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in astrocytes. Pentamidine 0-11 S100 protein, beta polypeptide, neural Mus musculus 69-74 26295040-5 2015 Pentamidine caused the reduction of glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in astrocytes. Pentamidine 0-11 MOK protein kinase Mus musculus 80-84 26295040-5 2015 Pentamidine caused the reduction of glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in astrocytes. Pentamidine 0-11 transformation related protein 53, pseudogene Mus musculus 154-157 26295040-7 2015 In parallel, we observed a significant neuroprotection exerted by pentamidine on CA1 pyramidal neurons. Pentamidine 66-77 carbonic anhydrase 1 Mus musculus 81-84 26295040-8 2015 We demonstrated that pentamidine inhibits Abeta-induced gliosis and neuroinflammation in an animal model of AD, thus playing a role in slowing down the course of the disease. Pentamidine 21-32 histocompatibility 2, class II antigen A, beta 1 Mus musculus 42-47 24307270-5 2014 Pentamidine, on the other hand, potently inhibits both MAO-A and MAO-B with IC50 values of 0.61 muM and 0.22 muM, respectively. Pentamidine 0-11 monoamine oxidase B Homo sapiens 65-70 24307270-7 2014 A kinetic analysis suggests that pentamidine acts as a competitive inhibitor with estimated Ki values of 0.41 muM and 0.22 muM for the inhibition of MAO-A and MAO-B, respectively. Pentamidine 33-44 monoamine oxidase A Homo sapiens 149-154 24307270-7 2014 A kinetic analysis suggests that pentamidine acts as a competitive inhibitor with estimated Ki values of 0.41 muM and 0.22 muM for the inhibition of MAO-A and MAO-B, respectively. Pentamidine 33-44 monoamine oxidase B Homo sapiens 159-164 25366487-0 2014 Effect of terfenadine and pentamidine on the HERG channel and its intracellular trafficking: combined analysis with automated voltage clamp and confocal microscopy. Pentamidine 26-37 potassium voltage-gated channel subfamily H member 2 Homo sapiens 45-49 24798287-1 2014 The antileishmanial activity of a series of bis-pyridinium derivatives that are analogues of pentamidine have been investigated, and all compounds assayed were found to display activity against promastigotes and intracellular amastigotes of Leishmania donovani and Leishmania major, with 50% effective concentrations (EC50s) lower than 1 muM in most cases. Pentamidine 93-104 latexin Homo sapiens 338-341 24564570-4 2014 Here we report diamidine compounds for specific inhibition of PRMT1, the primary type I enzyme. Pentamidine 15-24 protein arginine methyltransferase 1 Homo sapiens 62-67 25366487-1 2014 The effects of terfenadine and pentamidine on the human ether-a-go-go related gene (hERG) channel current and its intracellular trafficking were evaluated. Pentamidine 31-42 ETS transcription factor ERG Homo sapiens 84-88 25366487-5 2014 The two drugs inhibited hERG channel function through different mechanisms: terfenadine through direct channel blockade and pentamidine through inhibition of channel trafficking to the cell membrane. Pentamidine 124-135 ETS transcription factor ERG Homo sapiens 24-28 23264854-0 2012 Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B. Pentamidine 37-48 S100 calcium binding protein B Homo sapiens 98-103 24157839-0 2014 Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines. Pentamidine 97-107 Spi-1 proto-oncogene Homo sapiens 70-74 24157839-2 2014 We report the inhibition of the ETS-family member PU.1 with a panel of novel heterocyclic diamidines. Pentamidine 90-100 Spi-1 proto-oncogene Homo sapiens 50-54 24157839-5 2014 We showed that diamidines target the minor groove of AT-rich sequences on one or both sides of the consensus and disrupt PU.1 binding. Pentamidine 15-25 Spi-1 proto-oncogene Homo sapiens 121-125 24157839-8 2014 This study demonstrates that heterocyclic diamidines are capable of inhibiting PU.1 by targeting the flanking sequences and supports future efforts to develop agents for inhibiting specific members of the ETS family. Pentamidine 42-52 Spi-1 proto-oncogene Homo sapiens 79-83 23586323-4 2013 EXPERIMENTAL APPROACH: hERG and K(IR)2.1 trafficking in HEK293 cells was evaluated by Western blot and immunofluorescence microscopy after treatment with pentamidine and six pentamidine analogues, and correction with dofetilide and four dofetilide analogues that displayed different abilities to inhibit IKr . Pentamidine 154-165 ETS transcription factor ERG Homo sapiens 23-27 23586323-4 2013 EXPERIMENTAL APPROACH: hERG and K(IR)2.1 trafficking in HEK293 cells was evaluated by Western blot and immunofluorescence microscopy after treatment with pentamidine and six pentamidine analogues, and correction with dofetilide and four dofetilide analogues that displayed different abilities to inhibit IKr . Pentamidine 154-165 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 32-40 23586323-4 2013 EXPERIMENTAL APPROACH: hERG and K(IR)2.1 trafficking in HEK293 cells was evaluated by Western blot and immunofluorescence microscopy after treatment with pentamidine and six pentamidine analogues, and correction with dofetilide and four dofetilide analogues that displayed different abilities to inhibit IKr . Pentamidine 174-185 ETS transcription factor ERG Homo sapiens 23-27 23586323-4 2013 EXPERIMENTAL APPROACH: hERG and K(IR)2.1 trafficking in HEK293 cells was evaluated by Western blot and immunofluorescence microscopy after treatment with pentamidine and six pentamidine analogues, and correction with dofetilide and four dofetilide analogues that displayed different abilities to inhibit IKr . Pentamidine 174-185 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 32-40 23586323-6 2013 KEY RESULTS: Structural modifications of pentamidine differentially affected plasma membrane levels of hERG and K(IR)2.1. Pentamidine 41-52 ETS transcription factor ERG Homo sapiens 103-107 23586323-6 2013 KEY RESULTS: Structural modifications of pentamidine differentially affected plasma membrane levels of hERG and K(IR)2.1. Pentamidine 41-52 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 112-120 23586323-9 2013 Dofetilide corrected pentamidine-induced hERG, but not K(IR)2.1 trafficking defects. Pentamidine 21-32 ETS transcription factor ERG Homo sapiens 41-45 23192368-0 2013 Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine. Pentamidine 88-99 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 61-69 23192368-11 2013 Pentamidine (10 muM, 48 h) reduced K(IR)2.1 levels to 0.6 +- 0.1-fold, which could be rescued by Baf (3.2 +- 0.9), CPZ (1.2 +- 0.3), or Dyn (1.2 +- 0.3). Pentamidine 0-11 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 35-43 23192368-11 2013 Pentamidine (10 muM, 48 h) reduced K(IR)2.1 levels to 0.6 +- 0.1-fold, which could be rescued by Baf (3.2 +- 0.9), CPZ (1.2 +- 0.3), or Dyn (1.2 +- 0.3). Pentamidine 0-11 BAF nuclear assembly factor 1 Homo sapiens 97-100 23093599-8 2013 These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site. Pentamidine 115-124 ETS transcription factor ERG Homo sapiens 41-44 23093599-8 2013 These data showed for the first time the ERG/DNA complex modulation, both in vitro and in cells, by a heterocyclic diamidine that specifically targets a portion of the ERG DNA recognition site. Pentamidine 115-124 ETS transcription factor ERG Homo sapiens 168-171 23680637-5 2013 Functional studies using OCT1-specific substrate pentamidine showed transporter-mediated AP but not BL uptake in Caco-2 cells and human and mouse intestinal tissues. Pentamidine 49-60 solute carrier family 22 member 1 Homo sapiens 25-29 23680637-6 2013 OCT1 inhibition decreased AP uptake of pentamidine by ~50% in all three systems with no effect on BL uptake. Pentamidine 39-50 solute carrier family 22 member 1 Homo sapiens 0-4 23680637-7 2013 A short hairpin RNA-mediated OCT1 knockdown in Caco-2 cells decreased AP uptake of pentamidine by ~50% but did not alter BL uptake. Pentamidine 83-94 solute carrier family 22 member 1 Homo sapiens 29-33 23625347-0 2013 Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue. Pentamidine 55-66 potassium calcium-activated channel subfamily N member 4 Homo sapiens 31-34 23625347-4 2013 The diamine antiprotozoal drug pentamidine (P) acutely inhibits IK1 by plugging the cytoplasmic pore region of the channel. Pentamidine 31-42 potassium calcium-activated channel subfamily N member 4 Homo sapiens 64-67 23625347-6 2013 METHODS AND RESULTS: We analysed seven pentamidine analogues (PA-1 to PA-7) for IK1 blocking potency at 200 nM using inside-out patches from KIR2.1 expressing HEK-293 cells. Pentamidine 39-50 PAXIP1 associated glutamate rich protein 1 Homo sapiens 62-66 23625347-6 2013 METHODS AND RESULTS: We analysed seven pentamidine analogues (PA-1 to PA-7) for IK1 blocking potency at 200 nM using inside-out patches from KIR2.1 expressing HEK-293 cells. Pentamidine 39-50 potassium calcium-activated channel subfamily N member 4 Homo sapiens 80-83 23192368-13 2013 Pentamidine-induced downregulation of K(IR)2.1 can be rescued at the level of the plasma membrane, implying that acquired trafficking defects can be rescued. Pentamidine 0-11 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 38-46 23259641-2 2012 The antiprotozoal drug pentamidine directly blocks S100B activity. Pentamidine 23-34 S100 protein, beta polypeptide, neural Mus musculus 51-56 23259641-11 2012 CONCLUSIONS: Pentamidine exerts a marked anti-inflammatory effect in a mice model of acute colitis, likely targeting S100B activity. Pentamidine 13-24 S100 protein, beta polypeptide, neural Mus musculus 117-122 23264854-1 2012 Molecular Dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. Pentamidine 38-49 S100 calcium binding protein B Homo sapiens 50-55 23264854-1 2012 Molecular Dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. Pentamidine 38-49 S100 calcium binding protein B Homo sapiens 120-125 23264854-1 2012 Molecular Dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. Pentamidine 38-49 S100 calcium binding protein B Homo sapiens 120-125 23264854-1 2012 Molecular Dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. Pentamidine 88-99 S100 calcium binding protein B Homo sapiens 50-55 23264854-1 2012 Molecular Dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. Pentamidine 88-99 S100 calcium binding protein B Homo sapiens 50-55 22711816-9 2012 We conclude that the unconventional aquaglyceroporin, AQP2, renders cells sensitive to both melarsoprol and pentamidine and that loss of AQP2 function could explain cases of innate and acquired MPXR. Pentamidine 108-119 aquaporin 2 Homo sapiens 54-58 22938941-0 2012 Pentamidine sensitizes chronic myelogenous leukemia K562 cells to TRAIL-induced apoptosis. Pentamidine 0-11 TNF superfamily member 10 Homo sapiens 66-71 22968103-2 2012 Pentamidine has been reported to be a substrate of organic cation transporter 1 (OCT1). Pentamidine 0-11 solute carrier family 22 member 1 Rattus norvegicus 51-79 22968103-2 2012 Pentamidine has been reported to be a substrate of organic cation transporter 1 (OCT1). Pentamidine 0-11 solute carrier family 22 member 1 Rattus norvegicus 81-85 22414727-6 2012 In this article, we report the successful identification of six approved drugs out of the Drugbank as FXR modulators (ketoconazole, pentamidine, dobutamine, imatinib, papaverine and montelukast) by using a SOM for screening of the DrugBank database. Pentamidine 132-143 nuclear receptor subfamily 1 group H member 4 Homo sapiens 102-105 22574508-8 2012 The plasmin activity was inhibited by pentamidine, chlorambucil and aromatic bis-amines (IC50 = 0.1 - 8 mM), whereas the trypsin activity was influenced only by pentamidine. Pentamidine 38-49 plasminogen Homo sapiens 4-11 22046004-5 2012 The present study was designed to provide a more complete picture of how hERG surface expression is disrupted by pentamidine at the cellular and molecular levels. Pentamidine 113-124 ETS transcription factor ERG Homo sapiens 73-77 22046004-6 2012 Using biochemical and electrophysiological methods, we found that pentamidine exclusively inhibits hERG export from the endoplasmic reticulum to the cell surface in a heterologous expression system as well as in cardiomyocytes. Pentamidine 66-77 ETS transcription factor ERG Homo sapiens 99-103 22046004-8 2012 We used rescue experiments in combination with an extensive mutational analysis to locate an interaction site for pentamidine at phenylalanine 656, a crucial residue in the canonical drug binding site of terminally folded hERG. Pentamidine 114-125 ETS transcription factor ERG Homo sapiens 222-226 22046004-9 2012 Our data suggest that pentamidine binding to a folding intermediate of hERG arrests channel maturation in a conformational state that cannot be exported from the endoplasmic reticulum. Pentamidine 22-33 ETS transcription factor ERG Homo sapiens 71-75 22046004-0 2012 Molecular determinants of pentamidine-induced hERG trafficking inhibition. Pentamidine 26-37 ETS transcription factor ERG Homo sapiens 46-50 22046004-3 2012 At the same time, pentamidine reduces surface expression of the cardiac potassium channel I(Kr)/human ether a-go-go-related gene (hERG). Pentamidine 18-29 ETS transcription factor ERG Homo sapiens 130-134 21299635-0 2011 Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Pentamidine 98-109 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 20-27 23094078-3 2012 Herein we repurpose the antimicrobial agent pentamidine as a regulator of LMP-1 TMD-5 lateral interactions. Pentamidine 44-55 PDZ and LIM domain 7 Homo sapiens 74-85 21299635-2 2011 Human metabolism of pentamidine depends on cytochrome P450 2C19 (CYP2C19). Pentamidine 20-31 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 43-63 21299635-2 2011 Human metabolism of pentamidine depends on cytochrome P450 2C19 (CYP2C19). Pentamidine 20-31 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 65-72 21299635-3 2011 The frequency of mutant CYP2C19 forms with decreased function (from 2% of Caucasians to 30% of Asians and 79% of certain Polynesians), together with common use of CYP2C19 inhibitors in the alloSCT process, creates risk for impaired pentamidine clearance resulting in toxicity ordinarily expected only with high doses given for active infection. Pentamidine 232-243 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 24-31 21299635-3 2011 The frequency of mutant CYP2C19 forms with decreased function (from 2% of Caucasians to 30% of Asians and 79% of certain Polynesians), together with common use of CYP2C19 inhibitors in the alloSCT process, creates risk for impaired pentamidine clearance resulting in toxicity ordinarily expected only with high doses given for active infection. Pentamidine 232-243 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 163-170 21299635-9 2011 These findings encourage routine use of preemptive CYP2C19 genotyping in alloSCT patients considered for pentamidine. Pentamidine 105-116 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 51-58 20854810-0 2010 Design and screening of ASIC inhibitors based on aromatic diamidines for combating neurological disorders. Pentamidine 58-68 acid sensing ion channel subunit 1 Homo sapiens 24-28 21316841-0 2011 Pentamidine reduces expression of hypoxia-inducible factor-1alpha in DU145 and MDA-MB-231 cancer cells. Pentamidine 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 34-65 21316841-3 2011 In this study, we report that pentamidine inhibits expression of hypoxia-inducible factor (HIF)-1alpha in cancer cells. Pentamidine 30-41 hypoxia inducible factor 1 subunit alpha Homo sapiens 65-102 21316841-4 2011 Pentamidine decreased HIF-1alpha protein translation and enhanced its protein degradation in DU145 prostate cancer and MDA-MB-231 breast cancer cells. Pentamidine 0-11 hypoxia inducible factor 1 subunit alpha Homo sapiens 22-32 21316841-5 2011 In parallel with reduction of de novo synthesis of HIF-1alpha, pentamidine was able to suppress global protein translation, an effect accompanied by the reduction of eIF4F complex formation and also the induction of eIF2alpha phosphorylation. Pentamidine 63-74 hypoxia inducible factor 1 subunit alpha Homo sapiens 51-61 21316841-5 2011 In parallel with reduction of de novo synthesis of HIF-1alpha, pentamidine was able to suppress global protein translation, an effect accompanied by the reduction of eIF4F complex formation and also the induction of eIF2alpha phosphorylation. Pentamidine 63-74 eukaryotic translation initiation factor 2A Homo sapiens 216-225 21316841-6 2011 These results show that pentamidine is a potential inhibitor of HIF-1alpha and its potential as a cancer therapeutic reagent warrants further study. Pentamidine 24-35 hypoxia inducible factor 1 subunit alpha Homo sapiens 64-74 21114988-0 2011 Inhibition of lysosomal degradation rescues pentamidine-mediated decreases of K(IR)2.1 ion channel expression but not that of K(v)11.1. Pentamidine 44-55 potassium inwardly rectifying channel subfamily J member 2 Homo sapiens 78-86 21114988-5 2011 In HEK293 cells, pentamidine inhibits functional K(v)11.1 channels, responsible for I(Kr), by interfering at the level of full glycosylation, yielding less mature form of K(v)11.1 at the plasma membrane. Pentamidine 17-28 potassium voltage-gated channel modifier subfamily V member 2 Homo sapiens 49-57 21114988-5 2011 In HEK293 cells, pentamidine inhibits functional K(v)11.1 channels, responsible for I(Kr), by interfering at the level of full glycosylation, yielding less mature form of K(v)11.1 at the plasma membrane. Pentamidine 17-28 potassium voltage-gated channel modifier subfamily V member 2 Homo sapiens 171-179 20144237-3 2010 Therefore, we investigated whether a bisbenzamidine derivative, pentamidine, which can inhibit endoexonuclease activity, might influence DSB-induced damage responses via inhibition of MRE11. Pentamidine 64-75 MRE11 homolog, double strand break repair nuclease Homo sapiens 184-189 20721830-2 2010 Pentamidine, a diamidine, has been used for more than 60 years to treat human African trypanosomiasis (HAT); however, the drug must be administered parenterally and is active against first-stage HAT only, prior to the parasites causing neurological deterioration through invasion of the CNS. Pentamidine 0-11 transmembrane serine protease 11D Homo sapiens 103-106 20721830-2 2010 Pentamidine, a diamidine, has been used for more than 60 years to treat human African trypanosomiasis (HAT); however, the drug must be administered parenterally and is active against first-stage HAT only, prior to the parasites causing neurological deterioration through invasion of the CNS. Pentamidine 0-11 transmembrane serine protease 11D Homo sapiens 195-198 20721830-2 2010 Pentamidine, a diamidine, has been used for more than 60 years to treat human African trypanosomiasis (HAT); however, the drug must be administered parenterally and is active against first-stage HAT only, prior to the parasites causing neurological deterioration through invasion of the CNS. Pentamidine 15-24 transmembrane serine protease 11D Homo sapiens 103-106 20721830-4 2010 In this review, progress in the development of diamidines for the treatment of HAT is discussed. Pentamidine 47-57 transmembrane serine protease 11D Homo sapiens 79-82 20356563-3 2010 The crystallographic structures of bovine beta-trypsin in complex with the ligands were determined to a resolution of 1.57 A (diminazene) and 1.70 A (diminazene and pentamidine). Pentamidine 165-176 serine protease 1 Bos taurus 42-54 20356563-5 2010 Thermodynamic parameters for the association of pentamidine with beta-trypsin reveal that this inhibitor has about 1.3-fold lower affinity than diminazene. Pentamidine 48-59 serine protease 1 Bos taurus 65-77 20144237-4 2010 RESULTS: We first clarified that pentamidine inhibited MRE11 nuclease activity and also reduced ATM kinase activity in vitro. Pentamidine 33-44 MRE11 homolog, double strand break repair nuclease Homo sapiens 55-60 20144237-6 2010 Indeed, we found that pentamidine reduced the accumulation of gamma-H2AX, NBS1 and phospho-ATM at the sites of DSBs. Pentamidine 22-33 nibrin Homo sapiens 74-78 20144237-10 2010 We found that pentamidine repressed the activity of Tip60 acetyltransferase which is known to acetylate histone H2A and that knockdown of Tip60 by siRNA reduced HR activity. Pentamidine 14-25 lysine acetyltransferase 5 Homo sapiens 52-57 20144237-10 2010 We found that pentamidine repressed the activity of Tip60 acetyltransferase which is known to acetylate histone H2A and that knockdown of Tip60 by siRNA reduced HR activity. Pentamidine 14-25 lysine acetyltransferase 5 Homo sapiens 138-143 20144237-11 2010 CONCLUSION: These results indicate that inhibition of Tip60 as well as hMRE11 nuclease by pentamidine underlies the radiosensitizing effects of this compound making it an excellent sensitizer for radiotherapy or chemotherapy. Pentamidine 90-101 MRE11 homolog, double strand break repair nuclease Homo sapiens 71-77 19377065-12 2009 Other than quinacrine, we also found that an apigenin dimer (compound 9d), previously shown to be able to inhibit ABCB1-mediated cancer drug resistance in mammalian cells, can also increase the pentamidine susceptibility of Leishmania. Pentamidine 194-205 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 19822739-4 2009 We identified the small molecules pentamidine and neomycin B as compounds that disrupt MBNL1 binding to CUG repeats in vitro. Pentamidine 34-45 muscleblind like splicing regulator 1 Homo sapiens 87-92 19822739-6 2009 Pentamidine also significantly reduced the formation of ribonuclear foci in tissue culture cells, releasing MBNL1 from the foci in the treated cells. Pentamidine 0-11 muscleblind like splicing regulator 1 Homo sapiens 108-113 19966562-1 2010 Pentamidine is a small molecule inhibitor of the Ca(+)-binding protein S100B and disrupts the S100B-p53 protein-protein interaction; this is thought to restore wild-type p53 tumour suppressor function in melanoma. Pentamidine 0-11 S100 calcium binding protein B Homo sapiens 71-76 19966562-1 2010 Pentamidine is a small molecule inhibitor of the Ca(+)-binding protein S100B and disrupts the S100B-p53 protein-protein interaction; this is thought to restore wild-type p53 tumour suppressor function in melanoma. Pentamidine 0-11 S100 calcium binding protein B Homo sapiens 94-99 19966562-1 2010 Pentamidine is a small molecule inhibitor of the Ca(+)-binding protein S100B and disrupts the S100B-p53 protein-protein interaction; this is thought to restore wild-type p53 tumour suppressor function in melanoma. Pentamidine 0-11 tumor protein p53 Homo sapiens 100-103 19966562-1 2010 Pentamidine is a small molecule inhibitor of the Ca(+)-binding protein S100B and disrupts the S100B-p53 protein-protein interaction; this is thought to restore wild-type p53 tumour suppressor function in melanoma. Pentamidine 0-11 tumor protein p53 Homo sapiens 170-173 19764817-7 2009 The structures of two inhibitor complexes of hDAO, berenil and pentamidine, have been refined to resolutions of 2.1 and 2.2 A, respectively. Pentamidine 63-74 D-amino acid oxidase Homo sapiens 45-49 19652455-0 2009 Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs. Pentamidine 47-58 ETS transcription factor ERG Homo sapiens 70-74 19652455-2 2009 Recent in vitro studies have indicated that hERG trafficking inhibition may play an important role in the onset of pentamidine-induced long QT syndrome. Pentamidine 115-126 ETS transcription factor ERG Homo sapiens 44-48 19261919-0 2009 Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. Pentamidine 0-11 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 165-204 19261919-9 2009 Furthermore, pentamidine distribution to the CNS involved influx and efflux [via P-glycoprotein and multidrug resistance-associated protein (MRP)] transporters and was affected by the other antitrypanosomal agents, suramin, melarsoprol, and nifurtimox, but not eflornithine. Pentamidine 13-24 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 100-139 19261919-9 2009 Furthermore, pentamidine distribution to the CNS involved influx and efflux [via P-glycoprotein and multidrug resistance-associated protein (MRP)] transporters and was affected by the other antitrypanosomal agents, suramin, melarsoprol, and nifurtimox, but not eflornithine. Pentamidine 13-24 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 141-144 19261919-12 2009 However, coadministration of P-glycoprotein and/or MRP inhibitors with pentamidine or other diamidines might provide a means of improving efficacy against CNS stage HAT. Pentamidine 71-82 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mus musculus 51-54 18602402-0 2008 Divalent metal ion complexes of S100B in the absence and presence of pentamidine. Pentamidine 69-80 S100 calcium binding protein B Homo sapiens 32-37 18971316-5 2009 The results of [(3)H]1-methyl-4-phenylpyridinium uptake study showed that pentamidine is a potent inhibitor for all three OCT isoforms (IC50 < 20 microM), whereas furamidine is a potent inhibitor for hOCT1 and hOCT3 (IC50 < 21 microM) but a less potent inhibitor for hOCT2 (IC50 = 189.2 microM). Pentamidine 74-85 solute carrier family 22 member 1 Homo sapiens 203-208 18971316-5 2009 The results of [(3)H]1-methyl-4-phenylpyridinium uptake study showed that pentamidine is a potent inhibitor for all three OCT isoforms (IC50 < 20 microM), whereas furamidine is a potent inhibitor for hOCT1 and hOCT3 (IC50 < 21 microM) but a less potent inhibitor for hOCT2 (IC50 = 189.2 microM). Pentamidine 74-85 solute carrier family 22 member 3 Homo sapiens 213-218 18971316-5 2009 The results of [(3)H]1-methyl-4-phenylpyridinium uptake study showed that pentamidine is a potent inhibitor for all three OCT isoforms (IC50 < 20 microM), whereas furamidine is a potent inhibitor for hOCT1 and hOCT3 (IC50 < 21 microM) but a less potent inhibitor for hOCT2 (IC50 = 189.2 microM). Pentamidine 74-85 POU class 2 homeobox 2 Homo sapiens 273-278 18971316-6 2009 Both diamidines are good substrates for hOCT1 (Km = 36.4 and 6.1 microM, respectively), but neither is a substrate for hOCT2 or hOCT3. Pentamidine 5-15 solute carrier family 22 member 1 Homo sapiens 40-45 18971316-6 2009 Both diamidines are good substrates for hOCT1 (Km = 36.4 and 6.1 microM, respectively), but neither is a substrate for hOCT2 or hOCT3. Pentamidine 5-15 POU class 2 homeobox 2 Homo sapiens 119-124 18971316-6 2009 Both diamidines are good substrates for hOCT1 (Km = 36.4 and 6.1 microM, respectively), but neither is a substrate for hOCT2 or hOCT3. Pentamidine 5-15 solute carrier family 22 member 3 Homo sapiens 128-133 18971316-7 2009 The cytotoxicity of pentamidine and furamidine was 4.4- and 9.3-fold greater, respectively, in CHO-hOCT1 cells compared with the mock cells. Pentamidine 20-31 solute carrier family 22 member 1 Homo sapiens 99-104 18971316-9 2009 This is the first finding that dicationic drugs, such as pentamidine and furamidine, are substrates for hOCT1. Pentamidine 57-68 solute carrier family 22 member 1 Homo sapiens 104-109 18346045-0 2008 Inhibitory effects on cytochrome p450 enzymes of pentamidine and its amidoxime pro-drug. Pentamidine 49-60 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 22-37 17713798-6 2007 Additionally, we have tried to explain a mechanism for the action of pentamidine, the best-known S100B ligand, and have proposed two S100B--pentamidine structures. Pentamidine 69-80 S100 calcium binding protein B Homo sapiens 97-102 18666427-0 2008 Effects of netropsin and pentamidine amino analogues on the amidolytic activity of plasmin, trypsin and urokinase. Pentamidine 25-36 plasminogen Homo sapiens 83-90 18666427-3 2008 One of the pentamidine analogues (5) and two bis-netropsin like compounds (6, 8) were potent inhibitors of plasmin (IC50 equals 90 and 100 microM), whereas an analogue of netropsin (2) was trypsin inhibitor (IC50 = 100 microM). Pentamidine 11-22 plasminogen Homo sapiens 107-114 18056463-4 2007 This combination, CRx-026, inhibits the growth of tumor cell lines in vivo more effectively than either pentamidine or chlorpromazine alone. Pentamidine 104-115 cone-rod homeobox Homo sapiens 18-21 18509543-1 2008 Pentamidine has a long history in the treatment of human African trypanosomiasis (HAT) and leishmaniasis. Pentamidine 0-11 transmembrane serine protease 11D Homo sapiens 82-85 18509543-4 2008 We provide an overview of the various guidelines concerning HAT and leishmaniasis over the past decades and show the confusion in the calculation of the dosage of pentamidine in these guidelines and the subsequent published reports on clinical trials and reviews. Pentamidine 163-174 transmembrane serine protease 11D Homo sapiens 60-63 18509543-7 2008 There is thus a need for a new, more transparent and concise guideline concerning the dosage of pentamidine, at least in the treatment of HAT and leishmaniasis. Pentamidine 96-107 transmembrane serine protease 11D Homo sapiens 138-141 17956279-6 2007 Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Pentamidine 173-184 heat shock protein 90 alpha family class A member 1 Homo sapiens 38-43 17956279-6 2007 Important examples are antineoplastic Hsp90 (heat-shock protein 90) inhibitors such as (i) geldanamycin, (ii) the leukaemia drug arsenic trioxide, (iii) the antiprotozoical pentamidine, (iv) probucol, a cholesterol-lowering drug, and (v) fluoxetine, a widely used antidepressant. Pentamidine 173-184 heat shock protein 90 alpha family class A member 1 Homo sapiens 45-66 17713798-6 2007 Additionally, we have tried to explain a mechanism for the action of pentamidine, the best-known S100B ligand, and have proposed two S100B--pentamidine structures. Pentamidine 69-80 S100 calcium binding protein B Homo sapiens 133-138 17713798-6 2007 Additionally, we have tried to explain a mechanism for the action of pentamidine, the best-known S100B ligand, and have proposed two S100B--pentamidine structures. Pentamidine 140-151 S100 calcium binding protein B Homo sapiens 97-102 17713798-6 2007 Additionally, we have tried to explain a mechanism for the action of pentamidine, the best-known S100B ligand, and have proposed two S100B--pentamidine structures. Pentamidine 140-151 S100 calcium binding protein B Homo sapiens 133-138 17296729-5 2007 We show that Pnt, Ato, and Da regulate Dap expression directly through their respective binding sites precisely at the time when these transcription factors function to specify neural fates. Pentamidine 13-16 dacapo Drosophila melanogaster 39-42 17567017-0 2007 Multidrug-binding transcription factor QacR binds the bivalent aromatic diamidines DB75 and DB359 in multiple positions. Pentamidine 72-82 QacR Staphylococcus aureus 39-43 17567017-4 2007 Pentamidine, a bivalent aromatic diamidine, interacts with QacR differently as one positively charged benzamidine moiety is neutralized by the dipoles of side-chain and peptide backbone oxygens rather than a formal negative charge from proximal acidic residues. Pentamidine 0-11 QacR Staphylococcus aureus 59-63 17567017-4 2007 Pentamidine, a bivalent aromatic diamidine, interacts with QacR differently as one positively charged benzamidine moiety is neutralized by the dipoles of side-chain and peptide backbone oxygens rather than a formal negative charge from proximal acidic residues. Pentamidine 33-42 QacR Staphylococcus aureus 59-63 17466980-0 2007 Leishmania panamensis: comparative inhibition of nuclear DNA topoisomerase II enzymes from promastigotes and human macrophages reveals anti-parasite selectivity of fluoroquinolones, flavonoids and pentamidine. Pentamidine 197-208 LPMP_282420 Leishmania panamensis 57-77 16278312-5 2006 Since two of the drugs that were ineffective I(HERG) blockers, arsenic trioxide and pentamidine, have been associated with cardiac repolarization delays (QT interval lengthening) and torsades de pointes ventricular arrhythmias in patients, we chose to evaluate them further using the isolated perfused rabbit heart model. Pentamidine 84-95 potassium voltage-gated channel subfamily H member 2 Homo sapiens 47-51 16989817-6 2006 One of these compounds, pentamidine, increases frataxin levels in patient cells. Pentamidine 24-35 frataxin Homo sapiens 47-55 15711590-4 2005 The drug pentamidine, at near therapeutic concentrations that do not cause direct KCNH2 channel block, disrupts normal KCNH2 channel protein processing and maturation to reduce its surface membrane expression. Pentamidine 9-20 potassium voltage-gated channel subfamily H member 2 Homo sapiens 119-124 16035062-6 2005 Pentamidine and NAAGA inhibited complement and were effective in reducing CD11b upregulation with both PS and PS-PEG. Pentamidine 0-11 integrin subunit alpha M Homo sapiens 74-79 15711592-0 2005 Pentamidine reduces hERG expression to prolong the QT interval. Pentamidine 0-11 ETS transcription factor ERG Homo sapiens 20-24 15711592-8 2005 Taken together, our data imply that chronic administration of pentamidine at clinically relevant exposure reduces the membrane expression of the hERG channel, which may most likely be the major mechanism of QT prolongation and torsade de pointes reported in man. Pentamidine 62-73 ETS transcription factor ERG Homo sapiens 145-149 15711592-4 2005 Since the effective concentrations of pentamidine on the hERG channel and APD were much higher than clinically relevant exposures (approximately 1 microM free or lower), we speculated that this drug might not prolong the QT interval through direct inhibition of I(Kr) channel. Pentamidine 38-49 ETS transcription factor ERG Homo sapiens 57-61 14726520-5 2004 Here we report the crystal structures of QacR bound to two cytotoxic bivalent diamidines, pentamidine and hexamidine. Pentamidine 78-88 QacR Staphylococcus aureus 41-45 15340016-6 2005 After overnight exposure, however, pentamidine reduced hERG currents and inhibited trafficking and maturation of hERG with IC(50) values of 5 to 8 microM similar to therapeutic concentrations. Pentamidine 35-46 ETS transcription factor ERG Homo sapiens 55-59 15340016-6 2005 After overnight exposure, however, pentamidine reduced hERG currents and inhibited trafficking and maturation of hERG with IC(50) values of 5 to 8 microM similar to therapeutic concentrations. Pentamidine 35-46 ETS transcription factor ERG Homo sapiens 113-117 15340016-11 2005 We conclude that pentamidine prolongs the cardiac action potential by block of hERG trafficking and reduction of the number of functional hERG channels at the cell surface. Pentamidine 17-28 ETS transcription factor ERG Homo sapiens 79-83 15340016-11 2005 We conclude that pentamidine prolongs the cardiac action potential by block of hERG trafficking and reduction of the number of functional hERG channels at the cell surface. Pentamidine 17-28 ETS transcription factor ERG Homo sapiens 138-142 15340016-12 2005 We propose that pentamidine, like arsenic trioxide, produces QT prolongation and torsades de pointes in patients by inhibition of hERG trafficking. Pentamidine 16-27 ETS transcription factor ERG Homo sapiens 130-134 15493923-2 2004 In an effort to develop biologically active minor groove agents, we are preparing and exploring the DNA interactions of a systematic set of diamidine derivatives with a powerful array of methods including DNase I footprinting, biosensor-SPR methods, and X-ray crystallography. Pentamidine 140-149 sepiapterin reductase Homo sapiens 237-240 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 43-54 S100 calcium binding protein B Homo sapiens 79-84 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 43-54 S100 calcium binding protein B Homo sapiens 138-143 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 43-54 tumor protein p53 Homo sapiens 204-207 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 43-54 S100 calcium binding protein B Homo sapiens 138-143 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 177-188 S100 calcium binding protein B Homo sapiens 79-84 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 177-188 S100 calcium binding protein B Homo sapiens 138-143 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 177-188 tumor protein p53 Homo sapiens 204-207 15456252-6 2004 An NMR-docked model of one such inhibitor, pentamidine, bound to Ca(2+)-loaded S100B was calculated using intermolecular NOE data between S100B and the drug, and indicates that pentamidine binds into the p53 binding site on S100B defined by helices 3 and 4 and loop 2 (termed the hinge region). Pentamidine 177-188 S100 calcium binding protein B Homo sapiens 138-143 14726520-5 2004 Here we report the crystal structures of QacR bound to two cytotoxic bivalent diamidines, pentamidine and hexamidine. Pentamidine 90-101 QacR Staphylococcus aureus 41-45 14726520-9 2004 Pentamidine binds QacR in a novel fashion whereby one of its benzamidine groups interacts with residue Glu-63, and the other is neutralized by carbonyl and side chain oxygen atoms. Pentamidine 0-11 QacR Staphylococcus aureus 18-22 14622004-13 2003 Collectively, the SPR and footprinting results show that the consensus sequence 5"-(A/T)-TG-(A/T) represents the optimal site for cooperative dimerization of the heterocyclic diamidine DB293. Pentamidine 175-184 sepiapterin reductase Homo sapiens 18-21